CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | antiparkinson drug |
|
Accession: | CHEBI:48407
|
browse the term
|
Definition: | A drug used in the treatment of Parkinson's disease. |
Synonyms: | related_synonym: | antiparkinson agent |
| xref: | Wikipedia:Antiparkinson |
|
|
|
G |
Drd1 |
dopamine receptor D1 |
multiple interactions affects localization |
ISO |
A 77636 binds to and results in increased activity of DRD1 protein; SCH 23390 inhibits the reaction [A 77636 affects the localization of DRD1 protein]; SCH 23390 inhibits the reaction [A 77636 results in increased activity of DRD1 protein] |
CTD |
PMID:15985612 |
|
NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002
|
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
EXP |
[Fluoxetine co-treated with Amantadine] results in increased expression of BDNF mRNA |
CTD |
PMID:19211973 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Ifi27 |
interferon, alpha-inducible protein 27 |
increases expression |
ISO |
Amantadine results in increased expression of IFI27 mRNA |
CTD |
PMID:16756086 |
|
NCBI chr 6:122,590,461...122,596,996
Ensembl chr 6:122,590,472...122,779,294
|
|
G |
Ifnar1 |
interferon alpha and beta receptor subunit 1 |
affects expression |
ISO |
Amantadine affects the expression of IFNAR1 mRNA |
CTD |
PMID:16756086 |
|
NCBI chr11:30,725,774...30,752,227
Ensembl chr11:30,725,790...30,749,979
|
|
G |
Jak1 |
Janus kinase 1 |
increases expression |
ISO |
Amantadine results in increased expression of JAK1 protein |
CTD |
PMID:16756086 |
|
NCBI chr 5:115,780,248...115,888,841
Ensembl chr 5:115,780,248...115,888,926
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Amantadine results in decreased activity of KCNH2 protein |
CTD |
PMID:21158687 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Map2 |
microtubule-associated protein 2 |
decreases expression |
ISO |
Amantadine results in decreased expression of MAP2 mRNA |
CTD |
PMID:34748853 |
|
NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Oas2 |
2'-5' oligoadenylate synthetase 2 |
increases expression |
ISO |
Amantadine results in increased expression of OAS2 mRNA |
CTD |
PMID:16756086 |
|
NCBI chr12:35,802,824...35,830,778
Ensembl chr12:35,806,759...35,829,371
|
|
G |
Slc47a1 |
solute carrier family 47 member 1 |
multiple interactions |
ISO |
Amantadine inhibits the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:22419765 |
|
NCBI chr10:46,034,115...46,088,617
Ensembl chr10:46,034,122...46,087,637
|
|
G |
Slc47a2 |
solute carrier family 47 member 2 |
multiple interactions |
ISO |
Amantadine inhibits the reaction [SLC47A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:22419765 |
|
NCBI chr10:45,990,806...46,033,937
Ensembl chr10:45,991,095...46,033,904
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
[Amantadine co-treated with Ursodeoxycholic Acid co-treated with 7,7'-dimethoxy-(4,4'-bi-1,3-benzodioxole)-5,5'-dicarboxylic acid dimethyl ester] results in increased activity of STAT1 |
CTD |
PMID:15918519 |
|
NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Tdp1 |
tyrosyl-DNA phosphodiesterase 1 |
decreases activity |
ISO |
Amantadine analog results in decreased activity of TDP1 protein |
CTD |
PMID:29248742 |
|
NCBI chr 6:119,163,192...119,231,029
Ensembl chr 6:119,163,166...119,231,021
|
|
|
G |
Amy1 |
amylase alpha 1 |
multiple interactions |
EXP |
Apomorphine results in increased secretion of and results in increased activity of AMY1A protein; Atenolol inhibits the reaction [Apomorphine results in increased secretion of and results in increased activity of AMY1A protein]; Metoclopramide inhibits the reaction [Apomorphine results in increased secretion of and results in increased activity of AMY1A protein] |
CTD |
PMID:21173550 |
|
NCBI chr 2:201,382,678...201,397,487
Ensembl chr 2:201,382,675...201,397,816
|
|
G |
Avp |
arginine vasopressin |
increases expression multiple interactions |
ISO |
Apomorphine results in increased expression of AVP protein Metoclopramide inhibits the reaction [Apomorphine results in increased expression of AVP protein] |
CTD |
PMID:16575035 |
|
NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
multiple interactions |
ISO |
Apomorphine inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]; Apomorphine inhibits the reaction [BMP6 protein results in increased secretion of HAMP protein modified form] |
CTD |
PMID:25633564 |
|
NCBI chr17:26,318,121...26,469,034
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Bmpr1a |
bone morphogenetic protein receptor type 1A |
decreases expression |
ISO |
Apomorphine results in decreased expression of BMPR1A mRNA |
CTD |
PMID:25633564 |
|
NCBI chr16:9,736,390...9,829,825
Ensembl chr16:9,736,630...9,780,616
|
|
G |
Cck |
cholecystokinin |
multiple interactions decreases activity |
EXP |
Naloxone inhibits the reaction [CCK protein results in decreased activity of Apomorphine] |
CTD |
PMID:3561887 |
|
NCBI chr 8:121,153,499...121,160,194
Ensembl chr 8:121,153,500...121,160,084
|
|
G |
Cckbr |
cholecystokinin B receptor |
affects response to substance |
ISO |
CCKBR protein affects the susceptibility to Apomorphine |
CTD |
PMID:11702094 |
|
NCBI chr 1:159,771,733...159,781,738
Ensembl chr 1:159,771,733...159,814,881
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Apomorphine results in decreased activity of CYP1B1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Drd1 |
dopamine receptor D1 |
multiple interactions |
ISO |
[[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole; Raclopride inhibits the reaction [[[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole]; SCH 23390 inhibits the reaction [[[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole] Apomorphine binds to and results in increased activity of DRD1 protein; SCH 23390 inhibits the reaction [Apomorphine results in increased activity of DRD1 protein] |
CTD |
PMID:8103921 PMID:15985612 |
|
NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions affects response to substance increases response to substance |
EXP ISO |
Risperidone inhibits the reaction [Apomorphine binds to and results in increased activity of DRD2 protein] DRD2 protein affects the susceptibility to Apomorphine DRD2 protein results in increased susceptibility to Apomorphine [[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole; Raclopride inhibits the reaction [[[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole]; SCH 23390 inhibits the reaction [[[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole] |
CTD |
PMID:2571179 PMID:7520908 PMID:8103596 PMID:8103921 PMID:14639100 PMID:19497322 More...
|
|
NCBI chr 8:49,708,903...49,772,888
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Drd3 |
dopamine receptor D3 |
increases response to substance |
ISO |
DRD3 protein results in increased susceptibility to Apomorphine |
CTD |
PMID:19497322 |
|
NCBI chr11:56,879,689...56,931,901
Ensembl chr11:56,879,689...56,940,596
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
Apomorphine results in increased expression of FOS protein |
CTD |
PMID:10904129 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Furin |
furin (paired basic amino acid cleaving enzyme) |
decreases expression |
ISO |
Apomorphine results in decreased expression of FURIN mRNA |
CTD |
PMID:25633564 |
|
NCBI chr 1:134,348,142...134,361,182
Ensembl chr 1:134,348,144...134,364,314
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
multiple interactions |
EXP |
GDNF protein affects the susceptibility to [Apomorphine co-treated with Oxidopamine] |
CTD |
PMID:11771942 |
|
NCBI chr 2:56,893,992...56,919,935
Ensembl chr 2:56,895,010...56,917,209
|
|
G |
Gh1 |
growth hormone 1 |
increases secretion increases expression |
ISO |
Apomorphine results in increased secretion of GH1 protein Apomorphine results in increased expression of GH1 protein |
CTD |
PMID:993808 PMID:8889285 |
|
NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
multiple interactions decreases secretion decreases expression |
ISO |
Apomorphine inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]; Apomorphine inhibits the reaction [BMP6 protein results in increased secretion of HAMP protein modified form]; Apomorphine inhibits the reaction [IL6 protein results in increased expression of HAMP mRNA] Apomorphine results in decreased secretion of HAMP protein modified form Apomorphine results in decreased expression of HAMP mRNA |
CTD |
PMID:25633564 |
|
NCBI chr 1:86,170,926...86,172,865
Ensembl chr 1:86,170,901...86,172,891
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
multiple interactions |
EXP |
[1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Apomorphine; [8-Hydroxy-2-(di-n-propylamino)tetralin binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Apomorphine; tertatolol inhibits the reaction [[1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Apomorphine]; tertatolol inhibits the reaction [[8-Hydroxy-2-(di-n-propylamino)tetralin binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Apomorphine] |
CTD |
PMID:8539317 |
|
NCBI chr 2:36,694,174...36,695,442
Ensembl chr 2:36,694,174...36,695,442
|
|
G |
Htr6 |
5-hydroxytryptamine receptor 6 |
increases response to substance multiple interactions |
EXP |
HTR6 protein results in increased susceptibility to Apomorphine Ro4368554 inhibits the reaction [HTR6 protein results in increased susceptibility to Apomorphine] |
CTD |
PMID:17920665 |
|
NCBI chr 5:151,295,269...151,312,853
Ensembl chr 5:151,296,662...151,311,912
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
Apomorphine inhibits the reaction [IL6 protein results in increased expression of HAMP mRNA] |
CTD |
PMID:25633564 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Apomorphine inhibits the reaction [Oxidopamine results in increased phosphorylation of JUN protein] |
CTD |
PMID:14599342 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
increases activity |
ISO |
Apomorphine results in increased activity of ODC1 protein |
CTD |
PMID:10354516 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Penk |
proenkephalin |
multiple interactions |
EXP |
Apomorphine inhibits the reaction [Reserpine results in increased expression of PENK mRNA] |
CTD |
PMID:17719177 |
|
NCBI chr 5:17,183,799...17,189,160
Ensembl chr 5:17,183,806...17,189,129
|
|
G |
Prl |
prolactin |
decreases expression |
ISO |
Apomorphine results in decreased expression of PRL protein |
CTD |
PMID:8889285 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Pvalb |
parvalbumin |
affects expression |
EXP |
Apomorphine affects the expression of PVALB protein |
CTD |
PMID:15238432 |
|
NCBI chr 7:109,772,939...109,787,954
Ensembl chr 7:109,772,593...109,784,561
|
|
G |
Rgs9 |
regulator of G-protein signaling 9 |
affects response to substance |
ISO |
RGS9 affects the susceptibility to Apomorphine |
CTD |
PMID:15728856 |
|
NCBI chr10:94,195,265...94,270,892
Ensembl chr10:94,197,054...94,270,892
|
|
G |
Shh |
sonic hedgehog signaling molecule |
multiple interactions |
EXP |
SHH protein modified form affects the susceptibility to [Apomorphine co-treated with Oxidopamine] |
CTD |
PMID:11771942 |
|
NCBI chr 4:6,954,017...6,963,170
Ensembl chr 4:6,954,017...6,963,170
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Apomorphine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Syt7 |
synaptotagmin 7 |
multiple interactions |
EXP |
[Reserpine co-treated with Apomorphine] results in increased expression of SYT7 mRNA |
CTD |
PMID:17719177 |
|
NCBI chr 1:207,031,369...207,093,787
Ensembl chr 1:207,031,592...207,089,026
|
|
G |
Tac1 |
tachykinin, precursor 1 |
multiple interactions |
EXP |
Apomorphine promotes the reaction [Reserpine results in increased expression of TAC1 mRNA] |
CTD |
PMID:17719177 |
|
NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178
|
|
|
G |
Comt |
catechol-O-methyltransferase |
increases methylation |
ISO EXP |
COMT protein results in increased methylation of Benserazide |
CTD |
PMID:11160877 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Ddc |
dopa decarboxylase |
multiple interactions |
ISO |
Benserazide binds to and results in decreased activity of DDC protein |
CTD |
PMID:35151785 |
|
NCBI chr14:86,378,685...86,469,189
Ensembl chr14:86,378,685...86,469,208
|
|
G |
Drd1 |
dopamine receptor D1 |
multiple interactions |
EXP |
[Oxidopamine co-treated with levodopa methyl ester] promotes the reaction [Benserazide results in increased expression of DRD1 protein] |
CTD |
PMID:19399396 |
|
NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions |
EXP |
[Oxidopamine co-treated with levodopa methyl ester] inhibits the reaction [Benserazide results in increased expression of DRD2 protein] |
CTD |
PMID:19399396 |
|
NCBI chr 8:49,708,903...49,772,888
Ensembl chr 8:49,708,927...49,772,875
|
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
decreases activity |
ISO |
Benztropine results in decreased activity of ABCB4 protein |
CTD |
PMID:28437613 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Acot2 |
acyl-CoA thioesterase 2 |
increases expression |
ISO |
Benztropine results in increased expression of ACOT2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:103,611,744...103,619,404
Ensembl chr 6:103,611,544...103,619,245
|
|
G |
Actbl2 |
actin, beta-like 2 |
increases expression |
ISO |
Benztropine results in increased expression of ACTBL2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:42,858,020...42,860,767
Ensembl chr 2:42,858,020...42,860,767
|
|
G |
Actr1a |
actin related protein 1A |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of ACTR1A protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:245,237,821...245,256,618
Ensembl chr 1:245,237,826...245,256,495
|
|
G |
Actr3 |
actin related protein 3 |
decreases expression |
ISO |
Benztropine results in decreased expression of ACTR3 protein |
CTD |
PMID:34122009 |
|
NCBI chr13:36,800,739...36,843,837
Ensembl chr13:36,800,093...36,844,124
|
|
G |
Adsl |
adenylosuccinate lyase |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of ADSL protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:112,479,256...112,503,439
Ensembl chr 7:112,479,271...112,503,760
|
|
G |
Agps |
alkylglycerone phosphate synthase |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of AGPS protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:60,747,323...60,845,831
Ensembl chr 3:60,747,323...60,845,830
|
|
G |
Ak1 |
adenylate kinase 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of AK1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:15,912,431...15,923,045
Ensembl chr 3:15,912,485...15,923,041
|
|
G |
Anxa1 |
annexin A1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of ANXA1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343
|
|
G |
Anxa5 |
annexin A5 |
decreases expression |
ISO |
Benztropine results in decreased expression of ANXA5 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:119,314,007...119,344,703
Ensembl chr 2:119,314,007...119,353,369
|
|
G |
Anxa6 |
annexin A6 |
decreases expression |
ISO |
Benztropine results in decreased expression of ANXA6 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:39,101,395...39,156,483
Ensembl chr10:39,097,109...39,156,433
|
|
G |
Anxa7 |
annexin A7 |
increases expression |
ISO |
Benztropine results in increased expression of ANXA7 protein |
CTD |
PMID:34122009 |
|
NCBI chr15:3,821,798...3,849,659
Ensembl chr15:3,821,845...3,849,385
|
|
G |
Armt1 |
acidic residue methyltransferase 1 |
increases expression |
ISO |
Benztropine results in increased expression of ARMT1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:40,894,558...40,918,302
Ensembl chr 1:40,894,550...40,918,302
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
decreases expression |
ISO |
Benztropine results in decreased expression of ASNS protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Asph |
aspartate-beta-hydroxylase |
increases expression |
ISO |
Benztropine results in increased expression of ASPH protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:22,603,879...22,814,107
Ensembl chr 5:22,603,486...22,813,876
|
|
G |
Atp2a3 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3 |
increases expression |
ISO |
Benztropine results in increased expression of ATP2A3 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:57,581,742...57,612,758
Ensembl chr10:57,582,128...57,612,748
|
|
G |
Atp5f1c |
ATP synthase F1 subunit gamma |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of ATP5C1 protein |
CTD |
PMID:34122009 |
|
NCBI chr17:68,423,927...68,446,169
Ensembl chr17:68,423,909...68,608,367
|
|
G |
Atp6v1b2 |
ATPase H+ transporting V1 subunit B2 |
decreases expression |
ISO |
Benztropine results in decreased expression of ATP6V1B2 protein |
CTD |
PMID:34122009 |
|
NCBI chr16:20,617,515...20,641,651
Ensembl chr16:20,617,518...20,641,745
|
|
G |
Atxn10 |
ataxin 10 |
increases expression |
ISO |
Benztropine results in increased expression of ATXN10 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:116,441,768...116,565,093
Ensembl chr 7:116,441,613...116,565,087
|
|
G |
Baz1b |
bromodomain adjacent to zinc finger domain, 1B |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of BAZ1B protein |
CTD |
PMID:34122009 |
|
NCBI chr12:21,431,985...21,489,956
Ensembl chr12:21,431,985...21,490,426
|
|
G |
Bcar1 |
BCAR1 scaffold protein, Cas family member |
decreases expression |
ISO |
Benztropine results in decreased expression of BCAR1 protein |
CTD |
PMID:34122009 |
|
NCBI chr19:39,679,218...39,713,952
Ensembl chr19:39,679,204...39,713,907
|
|
G |
Bltp1 |
bridge-like lipid transfer protein family member 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of BLTP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:119,708,114...119,924,697
Ensembl chr 2:119,708,209...119,924,695
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
increases expression |
ISO |
Benztropine results in increased expression of BMP6 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr17:26,318,121...26,469,034
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Brd2 |
bromodomain containing 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of BRD2 protein |
CTD |
PMID:34122009 |
|
NCBI chr20:4,727,078...4,735,389
Ensembl chr20:4,728,151...4,735,388
|
|
G |
Bsg |
basigin (Ok blood group) |
decreases expression |
ISO |
Benztropine results in decreased expression of BSG protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:9,993,170...10,000,387
Ensembl chr 7:9,993,170...10,000,387
|
|
G |
Cald1 |
caldesmon 1 |
decreases expression multiple interactions |
ISO |
Benztropine results in decreased expression of CALD1 protein [Cuprizone co-treated with Benztropine] results in decreased expression of CALD1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:63,265,781...63,446,936
Ensembl chr 4:63,265,942...63,446,932
|
|
G |
Calu |
calumenin |
decreases expression |
ISO |
Benztropine results in decreased expression of CALU protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:57,949,086...57,976,589
Ensembl chr 4:57,948,997...57,976,593
|
|
G |
Camk2d |
calcium/calmodulin-dependent protein kinase II delta |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of CAMK2D protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:215,023,785...215,287,351
Ensembl chr 2:215,024,004...215,286,178
|
|
G |
Caprin1 |
cell cycle associated protein 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of CAPRIN1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:90,152,305...90,230,447
Ensembl chr 3:90,153,620...90,230,502
|
|
G |
Casp8ap2 |
caspase 8 associated protein 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of CASP8AP2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:47,014,501...47,052,276
Ensembl chr 5:47,014,667...47,052,275
|
|
G |
Cbx5 |
chromobox 5 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of CBX5 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:134,333,165...134,376,102
Ensembl chr 7:134,331,335...134,375,022
|
|
G |
Ccar1 |
cell division cycle and apoptosis regulator 1 |
increases expression |
ISO |
Benztropine results in increased expression of CCAR1 protein |
CTD |
PMID:34122009 |
|
NCBI chr20:30,685,916...30,728,531
Ensembl chr20:30,685,916...30,728,526
|
|
G |
Ccdc121rt |
coiled-coil domain containing 121, retrotransposed |
increases expression |
ISO |
Benztropine results in increased expression of CCDC121 protein |
CTD |
PMID:34122009 |
|
NCBI chr13:93,253,752...93,255,406
Ensembl chr13:93,254,387...93,255,358
|
|
G |
Cct6a |
chaperonin containing TCP1 subunit 6A |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of CCT6A protein |
CTD |
PMID:34122009 |
|
NCBI chr12:26,872,736...26,883,125
Ensembl chr12:26,872,574...26,883,337
|
|
G |
Cct7 |
chaperonin containing TCP1 subunit 7 |
decreases expression |
ISO |
Benztropine results in decreased expression of CCT7 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:117,989,232...118,006,478
Ensembl chr 4:117,989,232...118,006,580
|
|
G |
Cct8 |
chaperonin containing TCP1 subunit 8 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of CCT8 protein |
CTD |
PMID:34122009 |
|
NCBI chr11:26,710,370...26,722,079
Ensembl chr11:26,710,370...26,722,079
|
|
G |
Cd276 |
Cd276 molecule |
decreases expression |
ISO |
Benztropine results in decreased expression of CD276 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:58,937,751...58,968,082
Ensembl chr 8:58,937,751...58,968,380
|
|
G |
Cenpv |
centromere protein V |
increases expression |
ISO |
Benztropine results in increased expression of CENPV protein |
CTD |
PMID:34122009 |
|
NCBI chr10:47,214,479...47,228,552
Ensembl chr10:47,214,490...47,228,761
|
|
G |
Chd4 |
chromodomain helicase DNA binding protein 4 |
decreases expression |
ISO |
Benztropine results in decreased expression of CHD4 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:157,898,503...157,931,632
Ensembl chr 4:157,899,391...157,931,541
|
|
G |
Ckb |
creatine kinase B |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of CKB protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315
|
|
G |
Cnp |
2',3'-cyclic nucleotide 3' phosphodiesterase |
multiple interactions decreases expression |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of CNP protein Benztropine results in decreased expression of CNP protein |
CTD |
PMID:34122009 |
|
NCBI chr10:85,511,164...85,517,723
Ensembl chr10:85,511,160...85,517,720
|
|
G |
Col14a1 |
collagen type XIV alpha 1 chain |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of COL14A1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:86,722,093...86,937,215
Ensembl chr 7:86,722,094...86,937,214
|
|
G |
Col5a2 |
collagen type V alpha 2 chain |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of COL5A2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 9:47,448,736...47,598,396
Ensembl chr 9:47,448,736...47,598,154
|
|
G |
Cops4 |
COP9 signalosome subunit 4 |
decreases expression |
ISO |
Benztropine results in decreased expression of COPS4 protein |
CTD |
PMID:34122009 |
|
NCBI chr14:9,078,579...9,108,788
Ensembl chr14:9,078,576...9,108,887
|
|
G |
Coro1b |
coronin 1B |
decreases expression |
ISO |
Benztropine results in decreased expression of CORO1B protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:201,442,977...201,448,416
Ensembl chr 1:201,443,014...201,448,416
|
|
G |
Coro7 |
coronin 7 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of CORO7 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:10,880,299...10,941,001
Ensembl chr10:10,885,196...10,941,001
|
|
G |
Cpne3 |
copine 3 |
decreases expression |
ISO |
Benztropine results in decreased expression of CPNE3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:33,014,658...33,064,004
Ensembl chr 5:33,016,307...33,063,934
|
|
G |
Cpsf3 |
cleavage and polyadenylation specific factor 3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of CPSF3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:40,836,121...40,864,129
Ensembl chr 6:40,836,097...40,864,128
|
|
G |
Crtap |
cartilage associated protein |
increases expression |
ISO |
Benztropine results in increased expression of CRTAP protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:114,047,929...114,067,648
Ensembl chr 8:114,047,933...114,067,631
|
|
G |
Cryz |
crystallin zeta |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of CRYZ protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:243,552,037...243,580,369
Ensembl chr 2:243,552,119...243,579,758
|
|
G |
Csde1 |
cold shock domain containing E1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of CSDE1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:190,546,015...190,582,790
Ensembl chr 2:190,554,980...190,582,784
|
|
G |
Cstf2 |
cleavage stimulation factor subunit 2 |
decreases expression |
ISO |
Benztropine results in decreased expression of CSTF2 protein |
CTD |
PMID:34122009 |
|
NCBI chr X:97,253,559...97,279,476
Ensembl chr X:97,253,586...97,279,476
|
|
G |
Ctbp1 |
C-terminal binding protein 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of CTBP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr14:77,455,580...77,482,821
Ensembl chr14:77,455,696...77,482,821
|
|
G |
Cul2 |
cullin 2 |
increases expression |
ISO |
Benztropine results in increased expression of CUL2 protein |
CTD |
PMID:34122009 |
|
NCBI chr17:54,169,086...54,210,197
Ensembl chr17:54,169,086...54,209,968
|
|
G |
Cul4b |
cullin 4B |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of CUL4B protein |
CTD |
PMID:34122009 |
|
NCBI chr X:117,287,481...117,326,688
Ensembl chr X:117,287,484...117,326,688
|
|
G |
Dars2 |
aspartyl-tRNA synthetase 2 (mitochondrial) |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of DARS2 protein |
CTD |
PMID:34122009 |
|
NCBI chr13:73,308,726...73,336,558
Ensembl chr13:73,308,726...73,336,934
|
|
G |
Dazap1 |
DAZ associated protein 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of DAZAP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:9,423,673...9,448,116
Ensembl chr 7:9,424,178...9,538,818
|
|
G |
Dctn2 |
dynactin subunit 2 |
increases expression |
ISO |
Benztropine results in increased expression of DCTN2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:63,092,061...63,107,560
Ensembl chr 7:63,092,057...63,108,543
|
|
G |
Ddx17 |
DEAD-box helicase 17 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of DDX17 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:111,091,127...111,109,353
Ensembl chr 7:111,089,445...111,109,193
|
|
G |
Ddx3x |
DEAD-box helicase 3, X-linked |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of DDX3X protein |
CTD |
PMID:34122009 |
|
NCBI chr X:9,479,532...9,493,455
Ensembl chr X:9,479,532...9,493,168
|
|
G |
Dgcr6 |
DiGeorge syndrome critical region gene 6 |
decreases expression |
ISO |
Benztropine results in decreased expression of DGCR6 protein |
CTD |
PMID:34122009 |
|
NCBI chr11:82,927,725...82,932,823
Ensembl chr11:82,927,725...82,932,823
|
|
G |
Dhcr24 |
24-dehydrocholesterol reductase |
increases expression |
ISO |
Benztropine results in increased expression of DHCR24 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:121,344,637...121,368,853
Ensembl chr 5:121,344,575...121,371,137
|
|
G |
Dhx8 |
DEAH-box helicase 8 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of DHX8 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:86,667,641...86,705,454
Ensembl chr10:86,667,834...86,705,137
|
|
G |
Dlat |
dihydrolipoamide S-acetyltransferase |
multiple interactions increases expression |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of DLAT protein Benztropine results in increased expression of DLAT protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:50,979,151...51,004,435
Ensembl chr 8:50,978,051...51,004,479
|
|
G |
Dlg2 |
discs large MAGUK scaffold protein 2 |
increases expression |
ISO |
Benztropine results in increased expression of DLG2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:144,451,653...146,503,949
Ensembl chr 1:144,451,472...146,499,475
|
|
G |
Dnajb11 |
DnaJ heat shock protein family (Hsp40) member B11 |
increases expression |
ISO |
Benztropine results in increased expression of DNAJB11 protein |
CTD |
PMID:34122009 |
|
NCBI chr11:78,151,750...78,168,259
Ensembl chr11:78,150,429...78,180,407
|
|
G |
Dpp3 |
dipeptidylpeptidase 3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of DPP3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:202,204,683...202,228,501
Ensembl chr 1:202,204,693...202,228,541
|
|
G |
Dpysl2 |
dihydropyrimidinase-like 2 |
decreases expression |
ISO |
Benztropine results in decreased expression of DPYSL2 protein |
CTD |
PMID:34122009 |
|
NCBI chr15:41,005,551...41,111,724
Ensembl chr15:41,005,551...41,111,829
|
|
G |
Dpysl3 |
dihydropyrimidinase-like 3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of DPYSL3 protein |
CTD |
PMID:34122009 |
|
NCBI chr18:35,374,429...35,480,462
Ensembl chr18:35,377,181...35,480,157
|
|
G |
Dync1li1 |
dynein cytoplasmic 1 light intermediate chain 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of DYNC1LI1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:114,376,649...114,410,297
Ensembl chr 8:114,376,662...114,410,934
|
|
G |
Ebna1bp2 |
EBNA1 binding protein 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of EBNA1BP2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:132,148,164...132,152,730
Ensembl chr 5:132,148,143...132,153,267
|
|
G |
Eef1g |
eukaryotic translation elongation factor 1 gamma |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of EEF1G protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:205,860,713...205,871,319
Ensembl chr 1:205,860,698...205,872,382
|
|
G |
Eif2s3 |
eukaryotic translation initiation factor 2 subunit gamma |
increases expression |
ISO |
Benztropine results in increased expression of EIF2S3 protein |
CTD |
PMID:34122009 |
|
NCBI chr X:58,916,513...58,939,923
Ensembl chr X:58,917,490...58,940,686
|
|
G |
Eif3b |
eukaryotic translation initiation factor 3, subunit B |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of EIF3B protein |
CTD |
PMID:34122009 |
|
NCBI chr12:14,196,403...14,220,865
Ensembl chr12:14,196,403...14,220,886
|
|
G |
Eif3c |
eukaryotic translation initiation factor 3, subunit C |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of EIF3C protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:181,134,604...181,152,489
Ensembl chr 1:181,134,604...181,152,493
|
|
G |
Eif3h |
eukaryotic translation initiation factor 3, subunit H |
decreases expression |
ISO |
Benztropine results in decreased expression of EIF3H protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:83,091,045...83,174,436
Ensembl chr 7:83,091,039...83,174,451
|
|
G |
Eif3l |
eukaryotic translation initiation factor 3, subunit L |
increases expression multiple interactions |
ISO |
Benztropine results in increased expression of EIF3L protein [Cuprizone co-treated with Benztropine] results in decreased expression of EIF3L protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:110,652,565...110,663,614
Ensembl chr 7:110,627,107...110,663,614
|
|
G |
Eif5 |
eukaryotic translation initiation factor 5 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of EIF5 protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:130,589,200...130,597,656
Ensembl chr 6:130,589,143...130,597,656
|
|
G |
Eif5b |
eukaryotic translation initiation factor 5B |
multiple interactions increases expression |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of EIF5B protein Benztropine results in increased expression of EIF5B protein |
CTD |
PMID:34122009 |
|
NCBI chr 9:40,222,769...40,277,482
Ensembl chr 9:40,222,898...40,277,482
|
|
G |
Eif6 |
eukaryotic translation initiation factor 6 |
decreases expression |
ISO |
Benztropine results in decreased expression of EIF6 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:144,325,038...144,331,396
Ensembl chr 3:144,325,036...144,331,401
|
|
G |
Eno1 |
enolase 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of ENO1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336
|
|
G |
Ephb3 |
Eph receptor B3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of EPHB3 protein |
CTD |
PMID:34122009 |
|
NCBI chr11:79,840,668...79,859,467
Ensembl chr11:79,840,668...79,859,370
|
|
G |
Epn1 |
Epsin 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of EPN1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:68,742,491...68,760,507
Ensembl chr 1:68,742,789...68,758,874
|
|
G |
Eps8 |
epidermal growth factor receptor pathway substrate 8 |
decreases expression |
ISO |
Benztropine results in decreased expression of EPS8 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:170,388,378...170,486,873
Ensembl chr 4:170,388,378...170,486,873
|
|
G |
Erh |
ERH, mRNA splicing and mitosis factor |
increases expression |
ISO |
Benztropine results in increased expression of ERH protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:100,280,930...100,291,449
Ensembl chr 6:100,280,930...100,291,210
|
|
G |
Erlin2 |
ER lipid raft associated 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of ERLIN2 protein |
CTD |
PMID:34122009 |
|
NCBI chr16:65,017,654...65,034,184
Ensembl chr16:65,018,532...65,033,671
|
|
G |
Ewsr1 |
EWS RNA-binding protein 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of EWSR1 protein |
CTD |
PMID:34122009 |
|
NCBI chr14:79,965,365...79,994,108
Ensembl chr14:79,965,368...79,994,544
|
|
G |
Exosc9 |
exosome component 9 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of EXOSC9 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:119,416,028...119,426,981
Ensembl chr 2:119,388,715...119,427,051
|
|
G |
Ezr |
ezrin |
decreases expression |
ISO |
Benztropine results in decreased expression of EZR protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:46,967,961...47,011,505
Ensembl chr 1:46,967,658...47,011,505
|
|
G |
Fabp3 |
fatty acid binding protein 3 |
increases expression |
ISO |
Benztropine results in increased expression of FABP3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:142,651,956...142,658,718
|
|
G |
Fdps |
farnesyl diphosphate synthase |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of FDPS protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776
|
|
G |
Flot2 |
flotillin 2 |
increases expression |
ISO |
Benztropine results in increased expression of FLOT2 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:62,926,047...62,947,759
Ensembl chr10:62,920,665...62,947,756
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of FLT1 protein |
CTD |
PMID:34122009 |
|
NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
|
|
G |
Fyco1 |
FYVE and coiled-coil domain autophagy adaptor 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of FYCO1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:123,412,105...123,479,315
Ensembl chr 8:123,412,112...123,479,021
|
|
G |
G3bp2 |
G3BP stress granule assembly factor 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of G3BP2 protein |
CTD |
PMID:34122009 |
|
NCBI chr14:15,932,356...16,020,555
Ensembl chr14:15,987,417...16,020,548
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
decreases expression |
ISO |
Benztropine results in decreased expression of G6PD protein |
CTD |
PMID:34122009 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Galnt2 |
polypeptide N-acetylgalactosaminyltransferase 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of GALNT2 protein |
CTD |
PMID:34122009 |
|
NCBI chr19:52,213,226...52,324,816
Ensembl chr19:52,213,351...52,324,813
|
|
G |
Gart |
phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of GART protein |
CTD |
PMID:34122009 |
|
NCBI chr11:30,864,896...30,891,125
Ensembl chr11:30,865,889...30,891,125
|
|
G |
Gatad2b |
GATA zinc finger domain containing 2B |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of GATAD2B protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:175,748,594...175,829,837
Ensembl chr 2:175,749,433...175,825,542
|
|
G |
Gda |
guanine deaminase |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of GDA protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:218,903,045...218,982,360
Ensembl chr 1:218,906,815...218,982,416
|
|
G |
Gfpt1 |
glutamine fructose-6-phosphate transaminase 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of GFPT1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:119,496,691...119,546,472
Ensembl chr 4:119,496,714...119,546,471
|
|
G |
Ggct |
gamma-glutamyl cyclotransferase |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of GGCT protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:84,122,921...84,129,327
Ensembl chr 4:84,123,118...84,129,277
|
|
G |
Glrx3 |
glutaredoxin 3 |
increases expression |
ISO |
Benztropine results in increased expression of GLRX3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:192,241,707...192,272,012
Ensembl chr 1:192,241,701...192,272,010
|
|
G |
Gls |
glutaminase |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of GLS protein |
CTD |
PMID:34122009 |
|
NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900
|
|
G |
Gna12 |
G protein subunit alpha 12 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of GNA12 protein |
CTD |
PMID:34122009 |
|
NCBI chr12:13,805,580...13,886,255
Ensembl chr12:13,805,698...13,886,255
|
|
G |
Golga4 |
golgin A4 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of GOLGA4 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:118,208,200...118,285,003
|
|
G |
Golgb1 |
golgin B1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of GOLGB1 protein |
CTD |
PMID:34122009 |
|
NCBI chr11:63,843,179...63,900,665
Ensembl chr11:63,843,986...63,900,770
|
|
G |
Got2 |
glutamic-oxaloacetic transaminase 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of GOT2 protein |
CTD |
PMID:34122009 |
|
NCBI chr19:9,174,304...9,199,995
Ensembl chr19:9,174,311...9,199,994
|
|
G |
Gpi |
glucose-6-phosphate isomerase |
increases expression |
ISO |
Benztropine results in increased expression of GPI protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:86,828,211...86,856,077
Ensembl chr 1:86,828,216...86,856,086
|
|
G |
Gpkow |
G patch domain and KOW motifs |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of GPKOW protein |
CTD |
PMID:34122009 |
|
NCBI chr X:14,791,601...14,806,384
Ensembl chr X:14,791,610...14,806,384
|
|
G |
Gtf2e1 |
general transcription factor IIE subunit 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of GTF2E1 protein |
CTD |
PMID:34122009 |
|
NCBI chr11:63,182,073...63,215,349
Ensembl chr11:63,182,349...63,213,942
|
|
G |
Gtf2f1 |
general transcription factor IIF subunit 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of GTF2F1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 9:1,844,027...1,853,455
Ensembl chr 9:1,843,901...1,853,423
|
|
G |
Gtpbp4 |
GTP binding protein 4 |
increases expression |
ISO |
Benztropine results in increased expression of GTPBP4 protein |
CTD |
PMID:34122009 |
|
NCBI chr17:61,308,033...61,328,184
Ensembl chr17:61,308,014...61,418,009
|
|
G |
Gys1 |
glycogen synthase 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of GYS1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:95,915,443...95,935,292
Ensembl chr 1:95,915,443...95,935,292
|
|
G |
H2ac20 |
H2A clustered histone 20 |
increases expression |
ISO |
Benztropine results in increased expression of H2AC20 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:183,779,879...183,780,324
|
|
G |
Hacd3 |
3-hydroxyacyl-CoA dehydratase 3 |
increases expression |
ISO |
Benztropine results in increased expression of HACD3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:65,501,240...65,538,507
Ensembl chr 8:65,501,240...65,538,507
|
|
G |
Hadhb |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta |
increases expression |
ISO |
Benztropine results in increased expression of HADHB protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:26,153,572...26,187,668
Ensembl chr 6:26,153,578...26,184,869
|
|
G |
Hars1 |
histidyl-tRNA synthetase 1 |
increases expression |
ISO |
Benztropine results in increased expression of HARS protein |
CTD |
PMID:34122009 |
|
NCBI chr18:28,381,649...28,398,699
Ensembl chr18:28,381,655...28,398,740
|
|
G |
Hat1 |
histone acetyltransferase 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of HAT1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:56,217,344...56,265,021
Ensembl chr 3:56,217,342...56,275,517
|
|
G |
Hcfc1 |
host cell factor C1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of HCFC1 protein |
CTD |
PMID:34122009 |
|
NCBI chr X:151,687,779...151,712,688
Ensembl chr X:151,687,779...151,712,638
|
|
G |
Hmcn2 |
hemicentin 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of HMCN2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:14,588,353...14,738,320
Ensembl chr 3:14,588,662...14,738,025
|
|
G |
Hnrnpd |
heterogeneous nuclear ribonucleoprotein D |
decreases expression |
ISO |
Benztropine results in decreased expression of HNRNPD protein |
CTD |
PMID:34122009 |
|
NCBI chr14:9,615,375...9,638,975
Ensembl chr14:9,615,479...9,633,786
|
|
G |
Hnrnpk |
heterogeneous nuclear ribonucleoprotein K |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of HNRNPK protein |
CTD |
PMID:34122009 |
|
NCBI chr17:6,262,936...6,275,001
Ensembl chr17:6,262,998...6,274,997
|
|
G |
Hps3 |
HPS3, biogenesis of lysosomal organelles complex 2 subunit 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of HPS3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:102,484,574...102,527,580
Ensembl chr 2:102,484,574...102,526,047
|
|
G |
Hsd17b12 |
hydroxysteroid (17-beta) dehydrogenase 12 |
increases expression |
ISO |
Benztropine results in increased expression of HSD17B12 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:79,990,048...80,113,556
Ensembl chr 3:79,990,056...80,113,617
|
|
G |
Hsd17b4 |
hydroxysteroid (17-beta) dehydrogenase 4 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of HSD17B4 protein |
CTD |
PMID:34122009 |
|
NCBI chr18:43,328,903...43,417,950
Ensembl chr18:43,328,824...43,417,952
|
|
G |
Hsp90b1 |
heat shock protein 90 beta family member 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of HSP90B1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:21,110,431...21,124,762
Ensembl chr 7:21,110,457...21,124,788
|
|
G |
Idi1 |
isopentenyl-diphosphate delta isomerase 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of IDI1 protein |
CTD |
PMID:34122009 |
|
NCBI chr17:61,629,592...61,637,357
Ensembl chr17:61,629,594...61,637,357
|
|
G |
Il1a |
interleukin 1 alpha |
decreases expression |
ISO |
Benztropine results in decreased expression of IL1A mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression |
ISO |
Benztropine results in decreased expression of IL1B mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il24 |
interleukin 24 |
increases expression |
ISO |
Benztropine results in increased expression of IL24 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487
|
|
G |
Jam3 |
junctional adhesion molecule 3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of JAM3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:25,508,461...25,569,306
Ensembl chr 8:25,507,057...25,569,355
|
|
G |
Jpt2 |
Jupiter microtubule associated homolog 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of JPT2 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:13,963,135...13,983,212
Ensembl chr10:13,963,137...13,983,170
|
|
G |
Kars1 |
lysyl-tRNA synthetase 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of KARS protein |
CTD |
PMID:34122009 |
|
NCBI chr19:39,957,846...39,976,886
Ensembl chr19:39,957,846...39,977,632
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Benztropine results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kctd12 |
potassium channel tetramerization domain containing 12 |
decreases expression |
ISO |
Benztropine results in decreased expression of KCTD12 protein |
CTD |
PMID:34122009 |
|
NCBI chr15:79,800,077...79,806,064
Ensembl chr15:79,801,191...79,806,282
|
|
G |
Khdrbs1 |
KH RNA binding domain containing, signal transduction associated 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of KHDRBS1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:142,051,844...142,089,175
Ensembl chr 5:142,063,570...142,089,180
|
|
G |
Kif5c |
kinesin family member 5C |
decreases expression |
ISO |
Benztropine results in decreased expression of KIF5C protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:34,032,082...34,185,597
Ensembl chr 3:34,032,105...34,182,413
|
|
G |
Klhdc2 |
kelch domain containing 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of KLHDC2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:87,777,183...87,791,609
Ensembl chr 6:87,777,183...87,804,187
|
|
G |
Klhl41 |
kelch-like family member 41 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of KLHL41 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:54,434,291...54,447,415
Ensembl chr 3:54,434,234...54,449,222
|
|
G |
Kpna4 |
karyopherin subunit alpha 4 |
increases expression |
ISO |
Benztropine results in increased expression of KPNA4 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:153,319,380...153,381,085
Ensembl chr 2:153,324,273...153,381,081
|
|
G |
Ktn1 |
kinectin 1 |
multiple interactions decreases expression |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of KTN1 protein Benztropine results in decreased expression of KTN1 protein |
CTD |
PMID:34122009 |
|
NCBI chr15:20,913,665...21,002,588
Ensembl chr15:20,914,642...21,002,578
|
|
G |
Lactb2 |
lactamase, beta 2 |
increases expression |
ISO |
Benztropine results in increased expression of LACTB2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:5,569,080...5,591,843
Ensembl chr 5:5,569,067...5,596,429
|
|
G |
Lamb1 |
laminin subunit beta 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of LAMB1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:47,835,492...47,902,585
Ensembl chr 6:47,835,525...47,902,585
|
|
G |
Lamc1 |
laminin subunit gamma 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of LAMC1 protein |
CTD |
PMID:34122009 |
|
NCBI chr13:65,374,372...65,501,492
Ensembl chr13:65,374,372...65,501,492
|
|
G |
Lima1 |
LIM domain and actin binding 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of LIMA1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:130,901,717...131,001,573
Ensembl chr 7:130,901,717...131,001,473
|
|
G |
Lipa |
lipase A, lysosomal acid type |
increases expression |
ISO |
Benztropine results in increased expression of LIPA protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:232,024,351...232,167,329
Ensembl chr 1:232,024,356...232,057,633
|
|
G |
Lmod2 |
leiomodin 2 |
increases expression |
ISO |
Benztropine results in increased expression of LMOD2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:53,067,428...53,075,124
Ensembl chr 4:53,067,428...53,075,120
|
|
G |
Lss |
lanosterol synthase |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of LSS protein |
CTD |
PMID:34122009 |
|
NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762
|
|
G |
Lta4h |
leukotriene A4 hydrolase |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of LTA4H protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:27,969,796...28,001,600
Ensembl chr 7:27,969,789...28,001,600
|
|
G |
Luc7l |
LUC7-like |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of LUC7L protein |
CTD |
PMID:34122009 |
|
NCBI chr10:15,273,340...15,307,131
Ensembl chr10:15,273,348...15,303,112
|
|
G |
Magea9 |
MAGE family member A9 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of MAGEA9 protein |
CTD |
PMID:34122009 |
|
NCBI chr X:142,619,282...142,624,654
Ensembl chr X:142,619,395...142,624,653
|
|
G |
Maged2 |
MAGE family member D2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of MAGED2 protein |
CTD |
PMID:34122009 |
|
NCBI chr X:19,733,593...19,741,769
Ensembl chr X:19,733,597...19,740,477
|
|
G |
Map1s |
microtubule-associated protein 1S |
increases expression |
ISO |
Benztropine results in increased expression of MAP1S protein |
CTD |
PMID:34122009 |
|
NCBI chr16:18,516,759...18,527,777
Ensembl chr16:18,517,574...18,527,988
|
|
G |
Map4 |
microtubule-associated protein 4 |
decreases expression |
ISO |
Benztropine results in decreased expression of MAP4 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:109,925,233...110,064,370
Ensembl chr 8:109,925,575...110,064,362
|
|
G |
Mapre1 |
microtubule-associated protein, RP/EB family, member 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of MAPRE1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:142,218,846...142,246,990
Ensembl chr 3:142,212,955...142,246,983
|
|
G |
Marcksl1 |
MARCKS-like 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of MARCKSL1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:141,851,491...141,853,814
Ensembl chr 5:141,850,110...141,853,817
|
|
G |
Mat2b |
methionine adenosyltransferase 2B |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of MAT2B protein |
CTD |
PMID:34122009 |
|
NCBI chr10:25,106,928...25,122,982
Ensembl chr10:25,106,930...25,122,777
|
|
G |
Mboat7 |
membrane bound O-acyltransferase domain containing 7 |
decreases expression |
ISO |
Benztropine results in decreased expression of MBOAT7 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:65,525,206...65,539,538
Ensembl chr 1:65,525,213...65,539,538
|
|
G |
Mdh1 |
malate dehydrogenase 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of MDH1 protein |
CTD |
PMID:34122009 |
|
NCBI chr14:95,630,625...95,645,920
Ensembl chr14:95,630,306...95,645,925
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
increases expression |
ISO |
Benztropine results in increased expression of MET mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
|
|
G |
Metap2 |
methionyl aminopeptidase 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of METAP2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:28,412,771...28,440,458
Ensembl chr 7:28,411,608...28,440,434
|
|
G |
Mif |
macrophage migration inhibitory factor |
increases expression |
ISO |
Benztropine results in increased expression of MIF protein |
CTD |
PMID:34122009 |
|
NCBI chr20:12,790,919...12,791,784
Ensembl chr20:12,790,902...12,799,504
|
|
G |
Mtdh |
metadherin |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of MTDH protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:65,306,464...65,365,647
Ensembl chr 7:65,306,400...65,364,413
|
|
G |
Mthfd1l |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of MTHFD1L protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:40,443,926...40,632,911
Ensembl chr 1:40,444,008...40,632,905
|
|
G |
Myh3 |
myosin heavy chain 3 |
increases expression |
ISO |
Benztropine results in increased expression of MYH3 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:51,770,177...51,793,994
Ensembl chr10:51,770,177...51,793,992
|
|
G |
Nat10 |
N-acetyltransferase 10 |
decreases expression |
ISO |
Benztropine results in decreased expression of NAT10 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:90,111,643...90,151,644
Ensembl chr 3:90,111,645...90,149,927
|
|
G |
Ncbp1 |
nuclear cap binding protein subunit 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of NCBP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:60,416,023...60,449,004
Ensembl chr 5:60,415,982...60,449,089
|
|
G |
Nectin2 |
nectin cell adhesion molecule 2 |
decreases expression |
ISO |
Benztropine results in decreased expression of NECTIN2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:79,372,123...79,407,379
Ensembl chr 1:79,372,119...79,407,360
|
|
G |
Nnmt |
nicotinamide N-methyltransferase |
increases expression |
ISO |
Benztropine results in increased expression of NNMT protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:48,928,663...48,947,734
Ensembl chr 8:48,933,598...48,946,655
|
|
G |
Noc2l |
NOC2-like nucleolar associated transcriptional repressor |
increases expression |
ISO |
Benztropine results in increased expression of NOC2L protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:166,820,075...166,831,951
Ensembl chr 5:166,820,161...166,831,949
|
|
G |
Nsf |
N-ethylmaleimide sensitive factor, vesicle fusing ATPase |
decreases expression |
ISO |
Benztropine results in decreased expression of NSF protein |
CTD |
PMID:34122009 |
|
NCBI chr10:88,727,912...88,857,375
Ensembl chr10:88,727,912...88,857,386
|
|
G |
Nsfl1c |
NSFL1 cofactor |
decreases expression |
ISO |
Benztropine results in decreased expression of NSFL1C protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:139,978,306...140,002,876
Ensembl chr 3:139,978,301...140,002,870
|
|
G |
Numa1 |
nuclear mitotic apparatus protein 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of NUMA1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:156,297,907...156,372,855
Ensembl chr 1:156,326,259...156,372,855
|
|
G |
Nup153 |
nucleoporin 153 |
increases expression |
ISO |
Benztropine results in increased expression of NUP153 protein |
CTD |
PMID:34122009 |
|
NCBI chr17:17,972,217...18,024,876
Ensembl chr17:17,972,217...18,024,876
|
|
G |
Nup50 |
nucleoporin 50 |
increases expression |
ISO |
Benztropine results in increased expression of NUP50 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:116,047,960...116,065,231
Ensembl chr 7:116,048,021...116,066,905
|
|
G |
Nup54 |
nucleoporin 54 |
decreases expression |
ISO |
Benztropine results in decreased expression of NUP54 protein |
CTD |
PMID:34122009 |
|
NCBI chr14:15,617,630...15,636,029
Ensembl chr14:15,617,679...15,636,028
|
|
G |
Nup93 |
nucleoporin 93 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of NUP93 protein |
CTD |
PMID:34122009 |
|
NCBI chr19:10,684,214...10,788,009
Ensembl chr19:10,682,075...10,788,026
|
|
G |
Nxf1 |
nuclear RNA export factor 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of NXF1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:205,655,442...205,668,637
Ensembl chr 1:205,655,375...205,668,636
|
|
G |
Oat |
ornithine aminotransferase |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of OAT protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:187,347,862...187,367,644
Ensembl chr 1:187,347,865...187,367,682
|
|
G |
Ogdh |
oxoglutarate dehydrogenase |
decreases expression |
ISO |
Benztropine results in decreased expression of OGDH protein |
CTD |
PMID:34122009 |
|
NCBI chr14:81,150,021...81,217,479
Ensembl chr14:81,150,091...81,217,479
|
|
G |
Ola1 |
Obg-like ATPase 1 |
increases expression |
ISO |
Benztropine results in increased expression of OLA1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:57,966,896...58,085,955
Ensembl chr 3:57,966,896...58,084,480
|
|
G |
P4hb |
prolyl 4-hydroxylase subunit beta |
decreases expression |
ISO |
Benztropine results in decreased expression of P4HB protein |
CTD |
PMID:34122009 |
|
NCBI chr10:105,836,972...105,848,583
Ensembl chr10:105,836,982...105,848,500
|
|
G |
Pa2g4 |
proliferation-associated 2G4 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of PA2G4 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:984,795...992,264
Ensembl chr 7:983,971...992,331
|
|
G |
Pafah1b1 |
platelet-activating factor acetylhydrolase 1b, regulatory subunit 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of PAFAH1B1 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:59,533,042...59,591,808
Ensembl chr10:59,534,117...59,591,808
|
|
G |
Pag1 |
phosphoprotein membrane anchor with glycosphingolipid microdomains 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of PAG1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:91,935,378...92,076,937
Ensembl chr 2:92,057,216...92,069,849
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions decreases expression |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of PARP1 protein Benztropine results in decreased expression of PARP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pc |
pyruvate carboxylase |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of PC protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:201,799,374...201,898,412
Ensembl chr 1:201,804,267...201,898,380
|
|
G |
Pcbp1 |
poly(rC) binding protein 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of PCBP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:118,972,698...118,974,722
Ensembl chr 4:118,972,661...118,976,500
|
|
G |
Pcbp2 |
poly(rC) binding protein 2 |
decreases expression |
ISO |
Benztropine results in decreased expression of PCBP2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:133,605,480...133,631,312
Ensembl chr 7:133,605,573...133,629,863
|
|
G |
Pcdhga2 |
protocadherin gamma subfamily A, 2 |
decreases expression |
ISO |
Benztropine results in decreased expression of PCDHGA2 protein |
CTD |
PMID:34122009 |
|
NCBI chr18:29,493,954...29,667,865
Ensembl chr18:29,493,954...29,667,868
|
|
G |
Pcmt1 |
protein-L-isoaspartate (D-aspartate) O-methyltransferase 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of PCMT1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:2,111,756...2,160,354
Ensembl chr 1:2,111,763...2,159,201
|
|
G |
Pcnp |
PEST proteolytic signal containing nuclear protein |
increases expression |
ISO |
Benztropine results in increased expression of PCNP protein |
CTD |
PMID:34122009 |
|
NCBI chr11:44,592,766...44,607,372
Ensembl chr11:44,592,742...44,607,348
|
|
G |
Pdcl3 |
phosducin-like 3 |
decreases expression |
ISO |
Benztropine results in decreased expression of PDCL3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 9:41,234,322...41,243,769
Ensembl chr 9:41,234,234...41,243,735
|
|
G |
Pdia3 |
protein disulfide isomerase family A, member 3 |
decreases expression |
ISO |
Benztropine results in decreased expression of PDIA3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:108,388,189...108,412,013
Ensembl chr 3:108,388,245...108,413,236
|
|
G |
Pdia6 |
protein disulfide isomerase family A, member 6 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of PDIA6 protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:40,062,980...40,080,223
Ensembl chr 6:40,062,926...40,080,613
|
|
G |
Pdlim5 |
PDZ and LIM domain 5 |
decreases expression |
ISO |
Benztropine results in decreased expression of PDLIM5 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:230,952,251...231,120,329
Ensembl chr 2:230,952,248...231,120,275
|
|
G |
Pebp1 |
phosphatidylethanolamine binding protein 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of PEBP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr12:39,302,864...39,307,064
Ensembl chr12:39,302,840...39,307,862
|
|
G |
Pfn1 |
profilin 1 |
increases expression |
ISO |
Benztropine results in increased expression of PFN1 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:55,365,263...55,367,968
Ensembl chr10:55,365,262...55,527,631
|
|
G |
Pgk1 |
phosphoglycerate kinase 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of PGK1 protein |
CTD |
PMID:34122009 |
|
NCBI chr X:71,271,454...71,287,429
Ensembl chr X:71,271,440...71,287,418
|
|
G |
Pgm3 |
phosphoglucomutase 3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of PGM3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:87,517,931...87,536,034
Ensembl chr 8:87,517,701...87,536,022
|
|
G |
Phf14 |
PHD finger protein 14 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of PHF14 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:40,009,691...40,195,870
Ensembl chr 4:40,009,264...40,195,885
|
|
G |
Phgdh |
phosphoglycerate dehydrogenase |
decreases expression |
ISO |
Benztropine results in decreased expression of PHGDH protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:185,906,964...185,936,160
Ensembl chr 2:185,906,966...185,935,944
|
|
G |
Pid1 |
phosphotyrosine interaction domain containing 1 |
increases expression |
ISO |
Benztropine results in increased expression of PID1 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 9:85,284,335...85,503,035
Ensembl chr 9:85,284,335...85,503,044
|
|
G |
Pin1 |
peptidylprolyl cis/trans isomerase, NIMA-interacting 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of PIN1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:19,189,408...19,200,785
Ensembl chr 8:19,189,373...19,200,785
|
|
G |
Pmpca |
peptidase, mitochondrial processing subunit alpha |
increases expression |
ISO |
Benztropine results in increased expression of PMPCA protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:9,207,731...9,216,846
Ensembl chr 3:9,207,717...9,216,844
|
|
G |
Pnma1 |
PNMA family member 1 |
increases expression |
ISO |
Benztropine results in increased expression of PNMA1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:103,782,244...103,784,029
Ensembl chr 6:103,773,889...103,784,567
|
|
G |
Pnma8a |
PNMA family member 8A |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of PNMA8A protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:77,629,272...77,643,156
Ensembl chr 1:77,639,423...77,642,082
|
|
G |
Pon3 |
paraoxonase 3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of PON3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:33,356,983...33,383,681
Ensembl chr 4:33,349,168...33,383,855
|
|
G |
Ppa1 |
inorganic pyrophosphatase 1 |
multiple interactions increases expression |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of PPA1 protein Benztropine results in increased expression of PPA1 protein |
CTD |
PMID:34122009 |
|
NCBI chr20:29,590,733...29,617,711
Ensembl chr20:29,590,707...29,619,215
|
|
G |
Ppm1f |
protein phosphatase, Mg2+/Mn2+ dependent, 1F |
decreases expression |
ISO |
Benztropine results in decreased expression of PPM1F protein |
CTD |
PMID:34122009 |
|
NCBI chr11:84,064,422...84,094,410
Ensembl chr11:84,064,420...84,094,340
|
|
G |
Ppp1r12a |
protein phosphatase 1, regulatory subunit 12A |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of PPP1R12A protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:43,482,808...43,593,689
Ensembl chr 7:43,482,803...43,593,425
|
|
G |
Ppp1r14b |
protein phosphatase 1, regulatory (inhibitor) subunit 14B |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of PPP1R14B protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:204,165,210...204,167,320
Ensembl chr 1:204,163,299...204,167,319
|
|
G |
Ppp3ca |
protein phosphatase 3 catalytic subunit alpha |
increases expression |
ISO |
Benztropine results in increased expression of PPP3CA protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:225,165,981...225,440,978
Ensembl chr 2:225,165,766...225,438,974
|
|
G |
Prkar2a |
protein kinase cAMP-dependent type II regulatory subunit alpha |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of PRKAR2A protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:109,393,189...109,458,832
Ensembl chr 8:109,395,833...109,455,628
|
|
G |
Prkcsh |
protein kinase C substrate 80K-H |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of PRKCSH protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:20,534,787...20,546,493
Ensembl chr 8:20,534,880...20,546,492
|
|
G |
Prmt1 |
protein arginine methyltransferase 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of PRMT1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:95,458,853...95,468,176
Ensembl chr 1:95,458,850...95,468,345
|
|
G |
Prpf6 |
pre-mRNA processing factor 6 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of PRPF6 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:168,706,952...168,771,191
Ensembl chr 3:168,704,299...168,774,991
|
|
G |
Psma1 |
proteasome 20S subunit alpha 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of PSMA1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:168,442,421...168,453,440
Ensembl chr 1:168,440,936...168,453,472
|
|
G |
Psmb7 |
proteasome 20S subunit beta 7 |
decreases expression |
ISO |
Benztropine results in decreased expression of PSMB7 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:22,357,777...22,417,748
Ensembl chr 3:22,354,698...22,417,937
|
|
G |
Psmc1 |
proteasome 26S subunit, ATPase 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of PSMC1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:119,392,833...119,405,233
Ensembl chr 6:119,392,855...119,410,123
|
|
G |
Psmc3 |
proteasome 26S subunit, ATPase 3 |
increases expression |
ISO |
Benztropine results in increased expression of PSMC3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:77,031,825...77,037,207
Ensembl chr 3:77,031,825...77,043,358
|
|
G |
Psmd7 |
proteasome 26S subunit, non-ATPase 7 |
increases expression |
ISO |
Benztropine results in increased expression of PSMD7 protein |
CTD |
PMID:34122009 |
|
NCBI chr19:35,494,317...35,501,605
Ensembl chr19:35,494,316...35,501,588
|
|
G |
Ptcd3 |
Pentatricopeptide repeat domain 3 |
increases expression multiple interactions |
ISO |
Benztropine results in increased expression of PTCD3 protein [Cuprizone co-treated with Benztropine] results in decreased expression of PTCD3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:103,922,440...103,957,445
Ensembl chr 4:103,920,566...103,957,538
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
ISO |
Benztropine results in decreased expression of PTGS2 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptk7 |
protein tyrosine kinase 7 |
decreases expression |
ISO |
Benztropine results in decreased expression of PTK7 protein |
CTD |
PMID:34122009 |
|
NCBI chr 9:14,352,155...14,418,494
Ensembl chr 9:14,351,202...14,418,494
|
|
G |
Puf60 |
poly-U binding splicing factor 60 |
decreases expression |
ISO |
Benztropine results in decreased expression of PUF60 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:107,782,770...107,793,814
Ensembl chr 7:107,782,770...107,794,531
|
|
G |
Pwp2 |
PWP2, small subunit processome component |
increases expression |
ISO |
Benztropine results in increased expression of PWP2 protein |
CTD |
PMID:34122009 |
|
NCBI chr20:10,499,332...10,512,965
Ensembl chr20:10,499,363...10,513,640
|
|
G |
Pycr1 |
pyrroline-5-carboxylate reductase 1 |
increases expression |
ISO |
Benztropine results in increased expression of PYCR1 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:105,917,732...105,922,658
Ensembl chr10:105,917,680...105,922,549
|
|
G |
Qdpr |
quinoid dihydropteridine reductase |
decreases expression |
ISO |
Benztropine results in decreased expression of QDPR protein |
CTD |
PMID:34122009 |
|
NCBI chr14:65,670,251...65,683,853
Ensembl chr14:65,670,131...65,683,854
|
|
G |
Rack1 |
receptor for activated C kinase 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of RACK1 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:33,169,415...33,174,896
Ensembl chr10:33,169,169...33,174,975
|
|
G |
Rbm15 |
RNA binding motif protein 15 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of RBM15 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:194,945,717...194,954,523
Ensembl chr 2:194,945,974...194,954,703
|
|
G |
Ric8a |
RIC8 guanine nucleotide exchange factor A |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of RIC8A protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:195,935,162...195,941,469
Ensembl chr 1:195,935,349...195,941,467
|
|
G |
Rpl10a |
ribosomal protein L10A |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of RPL10A protein |
CTD |
PMID:34122009 |
|
NCBI chr20:6,388,800...6,391,358
Ensembl chr20:6,385,823...6,391,357
|
|
G |
Rpl19 |
ribosomal protein L19 |
increases expression |
ISO |
Benztropine results in increased expression of RPL19 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:83,022,503...83,026,030
Ensembl chr10:83,019,257...83,052,112
|
|
G |
Rpl24 |
ribosomal protein L24 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of RPL24 protein |
CTD |
PMID:34122009 |
|
NCBI chr11:44,653,937...44,659,346
Ensembl chr11:44,653,937...44,659,370
|
|
G |
Rpl30 |
ribosomal protein L30 |
increases expression |
ISO |
Benztropine results in increased expression of RPL30 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:65,648,470...65,651,363
Ensembl chr10:36,831,500...36,831,990 Ensembl chr 7:36,831,500...36,831,990 Ensembl chr10:36,831,500...36,831,990
|
|
G |
Rpl7a |
ribosomal protein L7A |
decreases expression |
ISO |
Benztropine results in decreased expression of RPL7A protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:10,239,026...10,241,703
Ensembl chr 3:10,239,001...10,241,716
|
|
G |
Rplp1 |
ribosomal protein lateral stalk subunit P1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of RPLP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:62,394,008...62,395,341
Ensembl chr 8:62,393,177...62,395,339
|
|
G |
Rps12 |
ribosomal protein S12 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of RPS12 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:21,680,854...21,683,010
Ensembl chr 1:21,680,852...21,683,014
|
|
G |
Rps18 |
ribosomal protein S18 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of RPS18 protein |
CTD |
PMID:34122009 |
|
NCBI chr20:4,931,427...4,935,538
Ensembl chr10:101,204,500...101,205,146 Ensembl chr20:101,204,500...101,205,146
|
|
G |
Rps27 |
ribosomal protein S27 |
increases expression |
ISO |
Benztropine results in increased expression of RPS27 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:175,665,858...175,666,963
Ensembl chr 2:175,665,853...175,666,964
|
|
G |
Rps27a |
ribosomal protein S27a |
increases expression |
ISO |
Benztropine results in increased expression of RPS27A protein |
CTD |
PMID:34122009 |
|
NCBI chr14:103,285,734...103,288,011
Ensembl chr14:103,285,734...103,288,011
|
|
G |
Rps3 |
ribosomal protein S3 |
decreases expression |
ISO |
Benztropine results in decreased expression of RPS3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:153,778,363...153,783,663
Ensembl chr 1:153,777,472...153,783,680
|
|
G |
Ruvbl2 |
RuvB-like AAA ATPase 2 |
increases expression |
ISO |
Benztropine results in increased expression of RUVBL2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:95,902,014...95,915,364
Ensembl chr 1:95,901,701...95,915,342
|
|
G |
Sae1 |
SUMO1 activating enzyme subunit 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of SAE1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:77,030,961...77,086,937
Ensembl chr 1:77,030,965...77,086,986
|
|
G |
Sars1 |
seryl-tRNA synthetase 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of SARS protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:196,065,543...196,081,240
Ensembl chr 2:196,065,430...196,081,277
|
|
G |
Satb2 |
SATB homeobox 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of SATB2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 9:58,348,027...58,534,256
Ensembl chr 9:58,350,246...58,530,707
|
|
G |
Sccpdh |
saccharopine dehydrogenase (putative) |
decreases expression |
ISO |
Benztropine results in decreased expression of SCCPDH protein |
CTD |
PMID:34122009 |
|
NCBI chr13:91,400,120...91,421,875
Ensembl chr13:91,400,190...91,422,222
|
|
G |
Sdcbp |
syndecan binding protein |
decreases expression |
ISO |
Benztropine results in decreased expression of SDCBP protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:19,473,499...19,517,188
Ensembl chr 5:19,489,961...19,527,572
|
|
G |
Sec23a |
Sec23 homolog A, COPII coat complex component |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of SEC23A protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:76,658,793...76,706,125
Ensembl chr 6:76,658,427...76,706,035
|
|
G |
Sec61b |
SEC61 translocon subunit beta |
increases expression |
ISO |
Benztropine results in increased expression of SEC61B protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:61,773,594...61,781,804
Ensembl chr 5:61,773,594...61,781,804
|
|
G |
Sec63 |
SEC63 homolog, protein translocation regulator |
increases expression |
ISO |
Benztropine results in increased expression of SEC63 protein |
CTD |
PMID:34122009 |
|
NCBI chr20:46,245,101...46,314,055
Ensembl chr20:46,245,101...46,314,055
|
|
G |
Serbp1 |
Serpine1 mRNA binding protein 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of SERBP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:96,401,587...96,421,816
Ensembl chr 4:96,401,477...96,421,813
|
|
G |
Serpinb3a |
serpin family B member 3A |
increases expression |
ISO |
Benztropine results in increased expression of SERPINB4 protein |
CTD |
PMID:34122009 |
|
NCBI chr13:23,241,303...23,246,328
Ensembl chr13:23,236,972...23,246,985
|
|
G |
Sf1 |
splicing factor 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of SF1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:203,670,016...203,683,432
Ensembl chr 1:203,670,018...203,684,330
|
|
G |
Sf3b3 |
splicing factor 3b, subunit 3 |
decreases expression |
ISO |
Benztropine results in decreased expression of SF3B3 protein |
CTD |
PMID:34122009 |
|
NCBI chr19:38,782,749...38,820,271
Ensembl chr19:38,783,040...38,820,245
|
|
G |
Sgca |
sarcoglycan, alpha |
decreases expression |
ISO |
Benztropine results in decreased expression of SGCA protein |
CTD |
PMID:34122009 |
|
NCBI chr10:79,904,698...79,922,813
Ensembl chr10:79,908,738...79,922,813
|
|
G |
Sh3pxd2b |
SH3 and PX domains 2B |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of SH3PXD2B protein |
CTD |
PMID:34122009 |
|
NCBI chr10:16,918,611...17,027,499
Ensembl chr10:16,918,679...17,005,170
|
|
G |
Shmt1 |
serine hydroxymethyltransferase 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of SHMT1 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:45,468,698...45,497,820
Ensembl chr10:45,468,700...45,497,820
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Benztropine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Slc25a6 |
solute carrier family 25 member 6 |
increases expression |
ISO |
Benztropine results in increased expression of SLC25A6 protein |
CTD |
PMID:34122009 |
|
NCBI chr18:68,571,229...68,572,474
Ensembl chr18:68,571,300...68,572,199
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of SLC2A1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Slc38a2 |
solute carrier family 38, member 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of SLC38A2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:127,851,267...127,863,482
Ensembl chr 7:127,851,267...127,863,436
|
|
G |
Slc3a2 |
solute carrier family 3 member 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of SLC3A2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:205,604,468...205,618,931
Ensembl chr 1:205,604,468...205,618,931
|
|
G |
Slc6a3 |
solute carrier family 6 member 3 |
multiple interactions |
ISO |
Benztropine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine] |
CTD |
PMID:17250655 |
|
NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413
|
|
G |
Slpi |
secretory leukocyte peptidase inhibitor |
increases expression |
ISO |
Benztropine results in increased expression of SLPI mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453
|
|
G |
Smarcb1 |
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of SMARCB1 protein |
CTD |
PMID:34122009 |
|
NCBI chr20:12,741,164...12,763,616
Ensembl chr20:12,741,477...12,763,620
|
|
G |
Smc3 |
structural maintenance of chromosomes 3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of SMC3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:252,601,422...252,644,522
Ensembl chr 1:252,601,753...252,644,522
|
|
G |
Smu1 |
SMU1, DNA replication regulator and spliceosomal factor |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of SMU1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:55,856,691...55,875,262
Ensembl chr 5:55,856,246...55,875,300
|
|
G |
Snrnp200 |
small nuclear ribonucleoprotein U5 subunit 200 |
multiple interactions increases expression |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of SNRNP200 protein Benztropine results in increased expression of SNRNP200 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:114,428,854...114,458,194
Ensembl chr 3:114,428,854...114,458,182
|
|
G |
Snrpa |
small nuclear ribonucleoprotein polypeptide A |
increases expression |
ISO |
Benztropine results in increased expression of SNRPA protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:82,481,770...82,490,540
Ensembl chr 1:82,481,770...82,490,538
|
|
G |
Snrpd2 |
small nuclear ribonucleoprotein D2 polypeptide |
increases expression |
ISO |
Benztropine results in increased expression of SNRPD2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:78,798,377...78,801,227
Ensembl chr 1:78,798,377...78,803,351
|
|
G |
Srek1 |
splicing regulatory glutamic acid and lysine rich protein 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of SREK1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:34,849,552...34,885,120
Ensembl chr 2:34,852,458...34,884,972
|
|
G |
Srsf5 |
serine and arginine rich splicing factor 5 |
increases expression |
ISO |
Benztropine results in increased expression of SRSF5 protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:100,605,165...100,610,192
Ensembl chr 6:100,605,456...100,610,177
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of STAT3 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Stim1 |
stromal interaction molecule 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of STIM1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:156,656,246...156,818,777
Ensembl chr 1:156,656,013...156,818,363
|
|
G |
Stip1 |
stress-induced phosphoprotein 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of STIP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:204,209,434...204,228,452
Ensembl chr 1:204,178,932...204,228,476
|
|
G |
Strap |
serine/threonine kinase receptor associated protein |
decreases expression |
ISO |
Benztropine results in decreased expression of STRAP protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:170,646,042...170,660,291
Ensembl chr 4:170,646,001...170,660,828
|
|
G |
Stub1 |
STIP1 homology and U-box containing protein 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of STUB1 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:14,850,765...14,853,046
Ensembl chr10:14,850,765...14,853,046
|
|
G |
Suclg1 |
succinate-CoA ligase GDP/ADP-forming subunit alpha |
decreases expression |
ISO |
Benztropine results in decreased expression of SUCLG1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:105,308,236...105,337,595
Ensembl chr 4:105,308,039...105,337,600
|
|
G |
Sumo2 |
small ubiquitin-like modifier 2 |
decreases expression |
ISO |
Benztropine results in decreased expression of SUMO2 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:100,771,941...100,784,503
Ensembl chr10:100,686,797...100,784,513
|
|
G |
Sun1 |
Sad1 and UNC84 domain containing 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of SUN1 protein |
CTD |
PMID:34122009 |
|
NCBI chr12:15,396,378...15,441,277
Ensembl chr12:15,396,381...15,441,571
|
|
G |
Syncrip |
synaptotagmin binding, cytoplasmic RNA interacting protein |
decreases expression |
ISO |
Benztropine results in decreased expression of SYNCRIP protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:89,402,487...89,435,517
Ensembl chr 8:89,402,866...89,435,515
|
|
G |
Tagln2 |
transgelin 2 |
decreases expression |
ISO |
Benztropine results in decreased expression of TAGLN2 protein |
CTD |
PMID:34122009 |
|
NCBI chr13:84,966,980...84,973,973
Ensembl chr13:84,967,009...84,973,972
|
|
G |
Tbcb |
tubulin folding cofactor B |
decreases expression |
ISO |
Benztropine results in decreased expression of TBCB protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:85,477,639...85,483,488
Ensembl chr 1:85,477,640...85,483,488
|
|
G |
Tcaf1 |
TRPM8 channel-associated factor 1 |
multiple interactions decreases expression |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of TCAF1 protein Benztropine results in decreased expression of TCAF1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:71,589,674...71,639,309
Ensembl chr 4:71,591,200...71,613,309
|
|
G |
Tgoln2 |
trans-golgi network protein 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of TGOLN2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:104,663,356...104,671,208
Ensembl chr 4:104,663,353...104,671,164
|
|
G |
Tln2 |
talin 2 |
decreases expression |
ISO |
Benztropine results in decreased expression of TLN2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:67,830,920...68,252,223
Ensembl chr 8:67,834,326...68,252,219
|
|
G |
Tmpo |
thymopoietin |
decreases expression |
ISO |
Benztropine results in decreased expression of TMPO protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:25,642,752...25,667,756
Ensembl chr 7:25,586,725...25,667,727
|
|
G |
Tnks1bp1 |
tankyrase 1 binding protein 1 |
multiple interactions decreases expression |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of TNKS1BP1 protein Benztropine results in decreased expression of TNKS1BP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:70,135,335...70,160,071
Ensembl chr 3:70,137,837...70,160,038
|
|
G |
Tomm34 |
translocase of outer mitochondrial membrane 34 |
decreases expression multiple interactions |
ISO |
Benztropine results in decreased expression of TOMM34 protein [Cuprizone co-treated with Benztropine] results in increased expression of TOMM34 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:152,729,345...152,746,295
Ensembl chr 3:152,729,349...152,746,373
|
|
G |
Top1mt |
DNA topoisomerase I mitochondrial |
increases expression |
ISO |
Benztropine results in increased expression of TOP1MT protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:107,338,092...107,368,125
Ensembl chr 7:107,342,527...107,366,049
|
|
G |
Tpm2 |
tropomyosin 2 |
decreases expression |
ISO |
Benztropine results in decreased expression of TPM2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:57,770,919...57,780,278
Ensembl chr 5:57,770,864...57,779,992
|
|
G |
Tpm3 |
tropomyosin 3 |
decreases expression |
ISO |
Benztropine results in decreased expression of TPM3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:175,517,198...175,545,014
Ensembl chr 2:175,517,226...175,545,013
|
|
G |
Tpr |
translocated promoter region, nuclear basket protein |
decreases expression |
ISO |
Benztropine results in decreased expression of TPR protein |
CTD |
PMID:34122009 |
|
NCBI chr13:62,424,312...62,487,502
Ensembl chr13:62,424,312...62,487,496
|
|
G |
Trim28 |
tripartite motif-containing 28 |
decreases expression multiple interactions |
ISO |
Benztropine results in decreased expression of TRIM28 protein [Cuprizone co-treated with Benztropine] results in increased expression of TRIM28 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:73,652,441...73,659,388
Ensembl chr 1:73,652,709...73,659,380
|
|
G |
Tspan3 |
tetraspanin 3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of TSPAN3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:56,546,067...56,569,815
Ensembl chr 8:56,546,069...56,569,880
|
|
G |
Ttc21a |
tetratricopeptide repeat domain 21A |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of TTC21A protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:119,667,044...119,702,028
Ensembl chr 8:119,666,933...119,702,456
|
|
G |
Ttyh2 |
tweety family member 2 |
increases expression |
ISO |
Benztropine results in increased expression of TTYH2 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:99,708,998...99,753,451
Ensembl chr10:99,709,007...99,753,444
|
|
G |
Ttyh3 |
tweety family member 3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of TTYH3 protein |
CTD |
PMID:34122009 |
|
NCBI chr12:13,996,831...14,025,457
Ensembl chr12:13,997,045...14,025,459
|
|
G |
Tubb5 |
tubulin, beta 5 class I |
increases expression |
ISO |
Benztropine results in increased expression of TUBB protein |
CTD |
PMID:34122009 |
|
NCBI chr20:2,912,779...2,916,928
Ensembl chr20:2,912,778...2,916,940
|
|
G |
Twf2 |
twinfilin actin-binding protein 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of TWF2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:106,845,253...106,858,298
Ensembl chr 8:106,845,253...106,858,298
|
|
G |
Txlna |
taxilin alpha |
decreases expression |
ISO |
Benztropine results in decreased expression of TXLNA protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:141,969,337...141,985,054
Ensembl chr 5:141,969,346...141,984,583
|
|
G |
Tyms |
thymidylate synthetase |
increases expression |
ISO |
Benztropine results in increased expression of TYMS protein |
CTD |
PMID:34122009 |
|
NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536
|
|
G |
U2af2 |
U2 small nuclear RNA auxiliary factor 2 |
decreases expression |
ISO |
Benztropine results in decreased expression of U2AF2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:68,760,911...68,779,730
Ensembl chr 1:68,760,924...68,778,492
|
|
G |
Uba2 |
ubiquitin-like modifier activating enzyme 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of UBA2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:86,775,239...86,802,685
Ensembl chr 1:86,775,244...86,802,682
|
|
G |
Ubap2l |
ubiquitin associated protein 2-like |
decreases expression |
ISO |
Benztropine results in decreased expression of UBAP2L protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:175,438,703...175,494,085
Ensembl chr 2:175,438,703...175,493,998
|
|
G |
Ubc |
ubiquitin C |
increases expression |
ISO |
Benztropine results in increased expression of UBC protein |
CTD |
PMID:34122009 |
|
NCBI chr12:31,238,889...31,243,924
Ensembl chr12:31,239,152...31,243,925
|
|
G |
Ubqln2 |
ubiquilin 2 |
decreases expression |
ISO |
Benztropine results in decreased expression of UBQLN2 protein |
CTD |
PMID:34122009 |
|
NCBI chr X:17,853,086...17,856,505
Ensembl chr X:17,853,114...17,856,505
|
|
G |
Uchl1 |
ubiquitin C-terminal hydrolase L1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of UCHL1 protein |
CTD |
PMID:34122009 |
|
NCBI chr14:41,485,033...41,495,590
Ensembl chr14:41,485,031...41,495,590
|
|
G |
Uchl3 |
ubiquitin C-terminal hydrolase L3 |
decreases expression |
ISO |
Benztropine results in decreased expression of UCHL3 protein |
CTD |
PMID:34122009 |
|
NCBI chr15:78,485,304...78,527,355
Ensembl chr15:78,485,315...78,527,355
|
|
G |
Ugdh |
UDP-glucose 6-dehydrogenase |
decreases expression |
ISO |
Benztropine results in decreased expression of UGDH protein |
CTD |
PMID:34122009 |
|
NCBI chr14:42,848,704...42,872,351
Ensembl chr14:42,848,854...42,872,354
|
|
G |
Unc45b |
unc-45 myosin chaperone B |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of UNC45B protein |
CTD |
PMID:34122009 |
|
NCBI chr10:67,845,382...67,873,389
Ensembl chr10:67,845,462...67,873,389
|
|
G |
Uqcrc2 |
ubiquinol cytochrome c reductase core protein 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of UQCRC2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:175,167,933...175,198,499
Ensembl chr 1:175,167,894...175,199,453
|
|
G |
Uso1 |
USO1 vesicle transport factor |
decreases expression |
ISO |
Benztropine results in decreased expression of USO1 protein |
CTD |
PMID:34122009 |
|
NCBI chr14:15,866,638...15,932,185
Ensembl chr14:15,866,638...15,932,171
|
|
G |
Usp10 |
ubiquitin specific peptidase 10 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of USP10 protein |
CTD |
PMID:34122009 |
|
NCBI chr19:47,972,858...48,014,900
Ensembl chr19:47,972,611...48,014,897
|
|
G |
Usp14 |
ubiquitin specific peptidase 14 |
increases expression |
ISO |
Benztropine results in increased expression of USP14 protein |
CTD |
PMID:34122009 |
|
NCBI chr18:1,018,111...1,057,727
Ensembl chr18:1,019,400...1,057,519
|
|
G |
Utp18 |
UTP18 small subunit processome component |
increases expression |
ISO |
Benztropine results in increased expression of UTP18 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:78,811,879...78,839,338
Ensembl chr10:78,811,880...78,839,627
|
|
G |
Vasp |
vasodilator-stimulated phosphoprotein |
decreases expression |
ISO |
Benztropine results in decreased expression of VASP protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:78,910,009...78,925,791
Ensembl chr 1:78,910,011...78,925,061
|
|
G |
Wars1 |
tryptophanyl-tRNA synthetase 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of WARS1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:127,776,088...127,807,273
Ensembl chr 6:127,776,090...127,807,269
|
|
G |
Wdr12 |
WD repeat domain 12 |
decreases expression |
ISO |
Benztropine results in decreased expression of WDR12 protein |
CTD |
PMID:34122009 |
|
NCBI chr 9:61,475,498...61,502,584
Ensembl chr 9:61,475,517...61,502,469
|
|
G |
Xirp2 |
xin actin-binding repeat containing 2 |
decreases expression |
ISO |
Benztropine results in decreased expression of XIRP2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:52,126,213...52,213,094
Ensembl chr 3:51,870,092...52,213,091
|
|
G |
Xpo7 |
exportin 7 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of XPO7 protein |
CTD |
PMID:34122009 |
|
NCBI chr15:45,742,053...45,828,050
Ensembl chr15:45,742,053...45,828,050
|
|
G |
Ywhaq |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, theta |
increases expression |
ISO |
Benztropine results in increased expression of YWHAQ protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:40,935,714...40,966,240
Ensembl chr 6:40,935,949...40,966,273
|
|
G |
Zbtb42 |
zinc finger and BTB domain containing 42 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of ZBTB42 protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:131,734,257...131,742,459
Ensembl chr 6:131,738,356...131,742,685
|
|
G |
Zfr |
zinc finger RNA binding protein |
decreases expression |
ISO |
Benztropine results in decreased expression of ZFR protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:61,137,611...61,200,322
Ensembl chr 2:61,137,611...61,200,322
|
|
G |
Zkscan7 |
zinc finger with KRAB and SCAN domains 7 |
decreases expression |
ISO |
Benztropine results in decreased expression of ZKSCAN7 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:122,501,938...122,519,600
Ensembl chr 8:122,502,218...122,519,600
|
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
decreases activity |
ISO |
Biperiden results in decreased activity of ABCB4 protein |
CTD |
PMID:28437613 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
increases expression |
ISO |
Biperiden results in increased expression of BMP6 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr17:26,318,121...26,469,034
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
multiple interactions |
EXP |
Biperiden binds to and results in decreased activity of CHRM1 protein |
CTD |
PMID:21336581 |
|
NCBI chr 1:205,567,046...205,583,001
Ensembl chr 1:205,567,220...205,582,356
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
Biperiden results in increased expression of EREG mRNA |
CTD |
PMID:32816093 |
|
NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
Biperiden results in increased expression of IL1A mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
Biperiden results in increased expression of IL1B mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il24 |
interleukin 24 |
increases expression |
ISO |
Biperiden results in increased expression of IL24 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
increases expression |
ISO |
Biperiden results in increased expression of MET mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
|
|
G |
Pid1 |
phosphotyrosine interaction domain containing 1 |
increases expression |
ISO |
Biperiden results in increased expression of PID1 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 9:85,284,335...85,503,035
Ensembl chr 9:85,284,335...85,503,044
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
increases expression |
ISO |
Biperiden results in increased expression of SLC7A11 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression multiple interactions |
EXP |
Bromocriptine results in increased expression of ABCB1 protein Clozapine inhibits the reaction [Bromocriptine results in increased expression of ABCB1 protein]; Spiperone inhibits the reaction [Bromocriptine results in increased expression of ABCB1 protein] |
CTD |
PMID:9111066 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
increases activity increases expression multiple interactions |
EXP |
Bromocriptine results in increased activity of ABCB1B promoter Bromocriptine results in increased expression of ABCB1B mRNA Clozapine inhibits the reaction [Bromocriptine results in increased activity of ABCB1B promoter]; eticlopride inhibits the reaction [Bromocriptine results in increased activity of ABCB1B promoter]; Pertussis Toxin inhibits the reaction [Bromocriptine results in increased activity of ABCB1B promoter]; Spiperone inhibits the reaction [Bromocriptine results in increased activity of ABCB1B promoter] |
CTD |
PMID:9111066 |
|
NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
increases expression multiple interactions |
EXP |
Bromocriptine results in increased expression of AKR1C3 mRNA methyl cellosolve inhibits the reaction [Bromocriptine results in increased expression of AKR1C3 mRNA] |
CTD |
PMID:21427058 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
ISO |
Bromocriptine results in increased expression of ATF3 mRNA; Bromocriptine results in increased expression of ATF3 protein |
CTD |
PMID:21867702 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
EXP |
Bromocriptine results in increased expression of BAX protein [Bromocriptine co-treated with Octreotide] results in increased expression of BAX protein |
CTD |
PMID:15046398 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
decreases secretion |
ISO |
Bromocriptine results in decreased secretion of BDNF protein |
CTD |
PMID:12770616 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
ISO |
[Bromocriptine co-treated with Estradiol] results in decreased expression of CTNNB1 protein |
CTD |
PMID:11786374 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions decreases expression |
EXP |
Bromocriptine inhibits the reaction [methyl cellosolve results in increased expression of CYP11A1 mRNA] Bromocriptine results in decreased expression of CYP11A1 protein |
CTD |
PMID:12742521 PMID:21427058 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
Bromocriptine results in decreased activity of CYP1A1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Bromocriptine results in decreased activity of CYP1B1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
affects metabolic processing multiple interactions affects binding |
ISO |
CYP3A4 protein affects the metabolism of Bromocriptine Bromocriptine inhibits the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin] Bromocriptine binds to CYP3A4 protein |
CTD |
PMID:15286053 PMID:17198380 PMID:19299527 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Dbh |
dopamine beta-hydroxylase |
decreases activity |
ISO |
Bromocriptine results in decreased activity of DBH protein |
CTD |
PMID:501350 |
|
NCBI chr 3:10,488,260...10,505,245
Ensembl chr 3:10,488,260...10,505,248
|
|
G |
Drd2 |
dopamine receptor D2 |
decreases expression multiple interactions increases expression increases response to substance affects expression affects response to substance |
EXP ISO |
Bromocriptine results in decreased expression of DRD2 mRNA [Clozapine co-treated with Bromocriptine] results in decreased expression of DRD2 mRNA Bromocriptine results in increased expression of DRD2 mRNA DRD2 polymorphism results in increased susceptibility to Bromocriptine Bromocriptine affects the expression of DRD2 mRNA DRD2 protein affects the susceptibility to Bromocriptine Bromocriptine binds to and results in increased activity of DRD2 mRNA; Bromocriptine promotes the reaction [Clozapine results in decreased expression of DRD2 mRNA] |
CTD |
PMID:1534540 PMID:8103596 PMID:15781964 PMID:16901644 PMID:20063113 |
|
NCBI chr 8:49,708,903...49,772,888
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Drd3 |
dopamine receptor D3 |
multiple interactions decreases expression |
EXP |
[1-Methyl-4-phenylpyridinium co-treated with Bromocriptine] results in decreased expression of DRD3 mRNA Bromocriptine results in decreased expression of DRD3 mRNA |
CTD |
PMID:17000468 |
|
NCBI chr11:56,879,689...56,931,901
Ensembl chr11:56,879,689...56,940,596
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
[Bromocriptine co-treated with Estradiol] results in increased expression of ESR1 protein |
CTD |
PMID:11786374 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
increases expression |
ISO |
Bromocriptine results in increased expression of FSHB protein |
CTD |
PMID:86031 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
decreases expression decreases secretion |
ISO |
Bromocriptine results in decreased expression of GDNF mRNA Bromocriptine results in decreased secretion of GDNF protein |
CTD |
PMID:12770616 |
|
NCBI chr 2:56,893,992...56,919,935
Ensembl chr 2:56,895,010...56,917,209
|
|
G |
Gh1 |
growth hormone 1 |
decreases expression increases expression |
ISO |
Bromocriptine results in decreased expression of GH1 protein Bromocriptine results in increased expression of GH1 protein |
CTD |
PMID:772175 PMID:3226523 PMID:3745407 PMID:7293648 PMID:19420816 |
|
NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
Bromocriptine results in increased expression of HMOX1 mRNA; Bromocriptine results in increased expression of HMOX1 protein |
CTD |
PMID:21867702 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Htr7 |
5-hydroxytryptamine receptor 7 |
multiple interactions |
ISO |
[Bromocriptine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Bromocriptine binds to and results in decreased activity of HTR7 protein |
CTD |
PMID:18996971 PMID:19509219 |
|
NCBI chr 1:233,636,442...233,761,063
Ensembl chr 1:233,636,452...233,760,626
|
|
G |
Ins2 |
insulin 2 |
decreases expression |
ISO |
Bromocriptine results in decreased expression of INS protein |
CTD |
PMID:16803851 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Lhb |
luteinizing hormone subunit beta |
increases expression |
ISO |
Bromocriptine results in increased expression of LHB protein |
CTD |
PMID:86031 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
EXP |
Bromocriptine promotes the reaction [Estrogens results in increased phosphorylation of and affects the localization of MAPK1 protein] |
CTD |
PMID:19595700 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP |
Bromocriptine promotes the reaction [Estrogens results in increased phosphorylation of and affects the localization of MAPK3 protein] |
CTD |
PMID:19595700 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases localization |
ISO |
Bromocriptine results in increased localization of NFE2L2 protein |
CTD |
PMID:21867702 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Ngf |
nerve growth factor |
increases secretion |
ISO |
Bromocriptine results in increased secretion of NGF protein |
CTD |
PMID:12770616 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Bromocriptine inhibits the reaction [SOD1 mutant form results in increased expression of NOS2 protein] |
CTD |
PMID:21867702 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nr5a2 |
nuclear receptor subfamily 5, group A, member 2 |
multiple interactions |
EXP |
Bromocriptine affects the reaction [methyl cellosolve results in increased expression of NR5A2 mRNA] |
CTD |
PMID:21427058 |
|
NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
EXP |
[Bromocriptine co-treated with vasoactive intestinal peptide, 4-chloro-Phe(6)-Leu(17)-] inhibits the reaction [Diethylstilbestrol results in increased expression of PCNA protein]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in increased expression of PCNA protein] |
CTD |
PMID:15677882 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pomc |
proopiomelanocortin |
decreases expression increases expression multiple interactions |
EXP ISO |
Bromocriptine results in decreased expression of POMC protein alternative form Bromocriptine results in increased expression of POMC mRNA; Bromocriptine results in increased expression of POMC protein modified form Bromocriptine inhibits the reaction [POMC protein results in decreased secretion of Corticosterone] |
CTD |
PMID:1325994 PMID:6274577 PMID:12742521 |
|
NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
|
|
G |
Prkcd |
protein kinase C, delta |
multiple interactions affects localization |
EXP |
Bromocriptine promotes the reaction [Estrogens results in increased expression of and results in increased cleavage of PRKCD protein] Bromocriptine affects the localization of PRKCD protein |
CTD |
PMID:19595700 |
|
NCBI chr16:5,769,226...5,807,214
Ensembl chr16:5,769,215...5,799,352
|
|
G |
Prl |
prolactin |
multiple interactions decreases expression decreases secretion |
ISO EXP |
Bromocriptine inhibits the reaction [Diethylstilbestrol results in increased secretion of PRL protein]; Bromocriptine inhibits the reaction [Nalorphine results in increased expression of PRL protein]; Bromocriptine inhibits the reaction [VIP protein results in increased expression of PRL protein] Bromocriptine results in decreased expression of PRL protein Bromocriptine results in decreased secretion of PRL protein Bromocriptine inhibits the reaction [Amisulpride results in increased secretion of PRL protein]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in increased expression of PRL mRNA]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in increased expression of PRL protein]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in increased secretion of PRL protein]; Bromocriptine inhibits the reaction [Estradiol results in increased expression of PRL protein]; Bromocriptine inhibits the reaction [methyl cellosolve results in increased expression of PRL protein]; Estradiol inhibits the reaction [Bromocriptine results in decreased secretion of PRL protein]; Ethanol inhibits the reaction [Bromocriptine results in decreased secretion of PRL protein]; Haloperidol inhibits the reaction [Bromocriptine results in decreased secretion of PRL protein]; Sulpiride inhibits the reaction [Bromocriptine results in decreased secretion of PRL protein] |
CTD |
PMID:86031 PMID:86795 PMID:90217 PMID:1407345 PMID:1874184 PMID:2042694 PMID:2887062 PMID:3019639 PMID:3208992 PMID:3625096 PMID:3660204 PMID:3745407 PMID:3776530 PMID:4072572 PMID:6441721 PMID:6477585 PMID:6507109 PMID:6669217 PMID:6693536 PMID:6986893 PMID:7106173 PMID:7168914 PMID:7243090 PMID:7670571 PMID:8914150 PMID:11685661 PMID:11786374 PMID:12106810 PMID:12161478 PMID:12742521 PMID:12824819 PMID:15046398 PMID:15677882 PMID:21427058 More...
|
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
multiple interactions |
EXP |
Bromocriptine inhibits the reaction [methyl cellosolve results in increased expression of SCARB1 mRNA] |
CTD |
PMID:21427058 |
|
NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
Bromocriptine inhibits the reaction [[SOD1 protein mutant form co-treated with Lipopolysaccharides] results in increased secretion of TNF protein]; Bromocriptine inhibits the reaction [SOD1 mutant form results in increased expression of NOS2 protein]; Bromocriptine inhibits the reaction [SOD1 mutant form results in increased expression of TNF protein] |
CTD |
PMID:21867702 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Star |
steroidogenic acute regulatory protein |
decreases expression |
EXP |
Bromocriptine results in decreased expression of STAR protein |
CTD |
PMID:12742521 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stat5a |
signal transducer and activator of transcription 5A |
affects localization |
ISO |
Bromocriptine affects the localization of STAT5A protein |
CTD |
PMID:17884938 |
|
NCBI chr10:85,785,537...85,809,869
Ensembl chr10:85,785,537...85,809,866
|
|
G |
Tgfa |
transforming growth factor alpha |
multiple interactions |
EXP |
Bromocriptine inhibits the reaction [Estradiol results in increased expression of TGFA mRNA] |
CTD |
PMID:1534540 |
|
NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
[Bromocriptine co-treated with vasoactive intestinal peptide, 4-chloro-Phe(6)-Leu(17)-] inhibits the reaction [Diethylstilbestrol results in increased expression of TGFB1 protein]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in decreased expression of TGFB1 protein] |
CTD |
PMID:15677882 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
Bromocriptine inhibits the reaction [[SOD1 protein mutant form co-treated with Lipopolysaccharides] results in increased secretion of TNF protein]; Bromocriptine inhibits the reaction [SOD1 mutant form results in increased expression of TNF protein] Bromocriptine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:11752888 PMID:21867702 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
EXP |
[Bromocriptine co-treated with vasoactive intestinal peptide, 4-chloro-Phe(6)-Leu(17)-] inhibits the reaction [Diethylstilbestrol results in increased expression of VEGFA protein]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in decreased expression of VEGFA protein] |
CTD |
PMID:15677882 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vip |
vasoactive intestinal peptide |
multiple interactions |
ISO EXP |
Bromocriptine inhibits the reaction [VIP protein results in increased expression of PRL protein] [Bromocriptine co-treated with vasoactive intestinal peptide, 4-chloro-Phe(6)-Leu(17)-] inhibits the reaction [Diethylstilbestrol results in increased expression of VIP protein]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in increased expression of VIP mRNA]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in increased expression of VIP protein] |
CTD |
PMID:6441721 PMID:15677882 |
|
NCBI chr 1:42,064,878...42,073,219
Ensembl chr 1:42,065,120...42,073,216
|
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
increases expression |
ISO |
Cabergoline results in increased expression of BDNF protein |
CTD |
PMID:35104500 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
increases expression |
ISO |
Cabergoline results in increased expression of CREB1 protein modified form |
CTD |
PMID:35104500 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions |
ISO |
Cabergoline binds to and results in increased activity of DRD2 protein |
CTD |
PMID:35104500 |
|
NCBI chr 8:49,708,903...49,772,888
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
increases expression increases secretion |
ISO |
cabergoline results in increased expression of GDNF mRNA cabergoline results in increased secretion of GDNF protein |
CTD |
PMID:12770616 |
|
NCBI chr 2:56,893,992...56,919,935
Ensembl chr 2:56,895,010...56,917,209
|
|
G |
Ngf |
nerve growth factor |
increases expression increases secretion |
ISO |
cabergoline results in increased expression of NGF mRNA cabergoline results in increased secretion of NGF protein |
CTD |
PMID:12770616 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Prl |
prolactin |
decreases expression multiple interactions decreases secretion |
ISO EXP |
cabergoline results in decreased expression of PRL protein Haloperidol inhibits the reaction [cabergoline results in decreased secretion of PRL protein]; Sulpiride inhibits the reaction [cabergoline results in decreased secretion of PRL protein] |
CTD |
PMID:2570719 PMID:3745407 PMID:7670571 PMID:15377706 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of BAX protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased expression of BAX protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of BAX protein]] [sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased expression of BAX protein]; Carbidopa inhibits the reaction [Cisplatin results in increased expression of BAX protein] |
CTD |
PMID:34560070 PMID:35202708 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of BCL2 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of BCL2 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of BCL2 protein]] [sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; Carbidopa inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein] |
CTD |
PMID:34560070 PMID:35202708 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP3 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP3 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP3 protein]] [sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; Carbidopa inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein] |
CTD |
PMID:34560070 PMID:35202708 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP9 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP9 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP9 protein]] [sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]; Carbidopa inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein] |
CTD |
PMID:34560070 PMID:35202708 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Comt |
catechol-O-methyltransferase |
increases methylation |
ISO EXP |
COMT protein results in increased methylation of Carbidopa |
CTD |
PMID:11160877 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Ddc |
dopa decarboxylase |
multiple interactions |
ISO |
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in increased expression of DDC mRNA] Carbidopa binds to and results in decreased activity of DDC protein |
CTD |
PMID:35151785 PMID:35202708 |
|
NCBI chr14:86,378,685...86,469,189
Ensembl chr14:86,378,685...86,469,208
|
|
G |
Dnm1l |
dynamin 1-like |
multiple interactions |
ISO |
Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of DNM1L protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased expression of DNM1L protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of DNM1L protein]] |
CTD |
PMID:35202708 |
|
NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482
|
|
G |
Fis1 |
fission, mitochondrial 1 |
multiple interactions |
ISO |
Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of FIS1 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased expression of FIS1 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of FIS1 protein]] |
CTD |
PMID:35202708 |
|
NCBI chr12:19,708,558...19,723,392
Ensembl chr12:19,708,558...19,723,377
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein]] |
CTD |
PMID:35202708 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased expression of IL1B protein] [sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased secretion of IL1B protein]; Carbidopa inhibits the reaction [Cisplatin results in increased secretion of IL1B protein] |
CTD |
PMID:34560070 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Maoa |
monoamine oxidase A |
multiple interactions |
ISO |
Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA mRNA]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA protein] [sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA mRNA]; [sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased expression of MAOA protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA mRNA]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA protein]; Carbidopa inhibits the reaction [Cisplatin results in increased expression of MAOA protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA protein]] |
CTD |
PMID:34560070 PMID:35202708 |
|
NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593
|
|
G |
Mfn1 |
mitofusin 1 |
multiple interactions |
ISO |
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in decreased expression of MFN1 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of MFN1 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of MFN1 protein]] |
CTD |
PMID:35202708 |
|
NCBI chr 2:115,313,380...115,359,651
Ensembl chr 2:115,313,401...115,359,640
|
|
G |
Mt-atp6 |
mitochondrially encoded ATP synthase membrane subunit 6 |
multiple interactions |
ISO |
Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of ATP6 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of ATP6 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of ATP6 protein]] |
CTD |
PMID:35202708 |
|
NCBI chr MT:7,919...8,599
Ensembl chr MT:7,919...8,599
|
|
G |
Mt-cyb |
mitochondrially encoded cytochrome b |
multiple interactions |
ISO |
Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of CYTB protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of CYTB protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of CYTB protein]] |
CTD |
PMID:35202708 |
|
NCBI chr MT:14,136...15,278
Ensembl chr MT:14,136...15,278
|
|
G |
Mt-nd1 |
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1 |
multiple interactions |
ISO |
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in decreased expression of ND1 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of ND1 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of ND1 protein]] |
CTD |
PMID:35202708 |
|
NCBI chr MT:2,740...3,694
Ensembl chr MT:2,740...3,694
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased phosphorylation of RELA protein]; Carbidopa inhibits the reaction [Cisplatin results in increased phosphorylation of RELA protein] |
CTD |
PMID:34560070 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased phosphorylation of STAT3 protein]; Carbidopa inhibits the reaction [Cisplatin results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:34560070 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased expression of TNF protein] [sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased secretion of TNF protein]; Carbidopa inhibits the reaction [Cisplatin results in increased secretion of TNF protein] |
CTD |
PMID:34560070 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tph1 |
tryptophan hydroxylase 1 |
multiple interactions |
ISO |
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in increased expression of TPH1 mRNA]; [sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in increased expression of TPH1 protein] |
CTD |
PMID:35202708 |
|
NCBI chr 1:97,157,375...97,178,415
Ensembl chr 1:97,157,409...97,178,344
|
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
carbinoxamine results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
carbinoxamine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
|
G |
Bche |
butyrylcholinesterase |
decreases activity |
ISO |
Dimenhydrinate results in decreased activity of BCHE protein |
CTD |
PMID:236606 |
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Dimenhydrinate inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
|
G |
Atg5 |
autophagy related 5 |
affects response to substance |
ISO |
ATG5 protein affects the susceptibility to Diphenhydramine |
CTD |
PMID:22310178 |
|
NCBI chr20:47,798,222...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Bche |
butyrylcholinesterase |
multiple interactions decreases activity |
ISO |
Protons affects the reaction [Diphenhydramine results in decreased activity of BCHE protein] |
CTD |
PMID:236606 |
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
decreases expression |
ISO |
Diphenhydramine results in decreased expression of BMP6 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr17:26,318,121...26,469,034
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Ereg |
epiregulin |
decreases expression |
ISO |
Diphenhydramine results in decreased expression of EREG mRNA |
CTD |
PMID:32816093 |
|
NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions |
ISO |
Diphenhydramine inhibits the reaction [Histamine results in increased expression of F3] |
CTD |
PMID:16009787 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Gnai1 |
G protein subunit alpha i1 |
increases response to substance |
ISO |
GNAI1 results in increased susceptibility to Diphenhydramine |
CTD |
PMID:14614911 |
|
NCBI chr 4:16,813,941...16,898,111
Ensembl chr 4:16,814,001...16,896,417
|
|
G |
Gnai2 |
G protein subunit alpha i2 |
increases response to substance |
ISO |
GNAI2 results in increased susceptibility to Diphenhydramine |
CTD |
PMID:14614911 |
|
NCBI chr 8:108,288,401...108,309,009
Ensembl chr 8:108,288,401...108,308,979
|
|
G |
Hrh1 |
histamine receptor H 1 |
multiple interactions |
ISO EXP |
Diphenhydramine binds to and results in decreased activity of HRH1 protein; Diphenhydramine binds to and results in increased activity of HRH1 protein; Diphenhydramine inhibits the reaction [Pyrilamine binds to HRH1 protein]; HRH1 protein promotes the reaction [Diphenhydramine results in decreased susceptibility to CXCL8 protein] [Diphenhydramine results in decreased activity of HRH1 protein] which results in decreased susceptibility to Erythromycin |
CTD |
PMID:1912125 PMID:2419744 PMID:2461127 PMID:7522859 PMID:9609743 PMID:12856827 More...
|
|
NCBI chr 4:147,564,781...147,649,353
Ensembl chr 4:147,645,995...147,647,455
|
|
G |
Il1b |
interleukin 1 beta |
increases expression decreases expression |
ISO |
Diphenhydramine results in increased expression of IL1B mRNA Diphenhydramine results in decreased expression of IL1B mRNA |
CTD |
PMID:28138970 PMID:32816093 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il24 |
interleukin 24 |
decreases expression |
ISO |
Diphenhydramine results in decreased expression of IL24 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
Diphenhydramine inhibits the reaction [Histamine results in increased expression of IL6 protein] |
CTD |
PMID:11336536 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases activity |
ISO |
Diphenhydramine results in increased activity of MAPK8 |
CTD |
PMID:17390763 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions |
ISO |
[Diphenhydramine co-treated with PK 11195] binds to and results in increased activity of NR1I3 protein alternative form |
CTD |
PMID:20869355 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Pla2g4a |
phospholipase A2 group IVA |
multiple interactions |
ISO |
Diphenhydramine inhibits the reaction [Histamine results in increased expression of PLA2G4A mRNA] |
CTD |
PMID:9609743 |
|
NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
ISO |
Diphenhydramine results in decreased expression of PTGS2 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
multiple interactions |
ISO |
Diphenhydramine inhibits the reaction [SLC22A1 protein results in increased transport of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:16263091 |
|
NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Diphenhydramine inhibits the reaction [SLC22A2 protein results in increased transport of 1-Methyl-4-phenylpyridinium]; Diphenhydramine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:16263091 PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Slc22a3 |
solute carrier family 22 member 3 |
multiple interactions |
ISO |
Diphenhydramine inhibits the reaction [SLC22A3 protein results in increased transport of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:16263091 |
|
NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612
|
|
G |
Slc22a5 |
solute carrier family 22 member 5 |
multiple interactions |
ISO |
Diphenhydramine affects the reaction [SLC22A5 gene mutant form affects the transport of and affects the abundance of Pyrilamine]; Diphenhydramine inhibits the reaction [SLC22A5 gene mutant form affects the transport of and affects the abundance of Pyrilamine] |
CTD |
PMID:19821448 |
|
NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
decreases expression |
ISO |
Diphenhydramine results in decreased expression of SLC7A11 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Slpi |
secretory leukocyte peptidase inhibitor |
increases expression |
ISO |
Diphenhydramine results in increased expression of SLPI mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453
|
|
|
G |
Acox3 |
acyl-CoA oxidase 3, pristanoyl |
affects binding |
EXP |
entacapone binds to ACOX3 protein |
CTD |
PMID:19783845 |
|
NCBI chr14:75,133,986...75,176,767
Ensembl chr14:75,094,676...75,176,205
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
affects binding |
EXP |
entacapone binds to ACSL1 protein |
CTD |
PMID:19783845 |
|
NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541
|
|
G |
Adprhl1 |
ADP-ribosylhydrolase like 1 |
affects binding |
EXP |
entacapone binds to ADPRHL1 protein |
CTD |
PMID:19783845 |
|
NCBI chr16:76,283,199...76,298,614 NCBI chr16:76,298,777...76,315,075
Ensembl chr16:76,283,103...76,354,440
|
|
G |
Auh |
AU RNA binding methylglutaconyl-CoA hydratase |
affects binding |
EXP |
entacapone binds to AUH protein |
CTD |
PMID:19783845 |
|
NCBI chr17:12,329,522...12,424,896
Ensembl chr17:12,329,524...12,424,896
|
|
G |
Cltc |
clathrin heavy chain |
affects binding |
EXP |
entacapone binds to CLTC protein |
CTD |
PMID:19783845 |
|
NCBI chr10:71,517,661...71,574,591
Ensembl chr10:71,517,663...71,573,737
|
|
G |
Comt |
catechol-O-methyltransferase |
decreases activity affects binding multiple interactions |
ISO EXP |
entacapone results in decreased activity of COMT protein entacapone binds to COMT protein [entacapone results in decreased activity of COMT protein] which results in increased abundance of Dopamine; entacapone inhibits the reaction [COMT protein results in increased methylation of Levodopa] |
CTD |
PMID:12898346 PMID:15566291 PMID:19783845 PMID:20334432 PMID:23206800 PMID:29688484 More...
|
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Echs1 |
enoyl-CoA hydratase, short chain 1 |
affects binding |
EXP |
entacapone binds to ECHS1 protein |
CTD |
PMID:19783845 |
|
NCBI chr 1:194,895,036...194,903,863
Ensembl chr 1:194,895,036...194,903,884
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
entacapone results in increased expression of EREG mRNA |
CTD |
PMID:32816093 |
|
NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
|
|
G |
Gpam |
glycerol-3-phosphate acyltransferase, mitochondrial |
decreases expression |
ISO |
entacapone results in decreased expression of GPAM protein |
CTD |
PMID:29688484 |
|
NCBI chr 1:254,106,323...254,170,755
Ensembl chr 1:254,106,331...254,142,639
|
|
G |
Hbb |
hemoglobin subunit beta |
affects binding |
EXP |
entacapone binds to HBB protein |
CTD |
PMID:19783845 |
|
NCBI chr 1:158,250,421...158,251,832
Ensembl chr 1:158,120,200...158,252,012
|
|
G |
Hsd17b13 |
hydroxysteroid (17-beta) dehydrogenase 13 |
affects binding |
EXP |
entacapone binds to HSD17B13 protein |
CTD |
PMID:19783845 |
|
NCBI chr14:5,751,697...5,766,809
Ensembl chr14:5,752,132...5,768,166
|
|
G |
Hsd17b4 |
hydroxysteroid (17-beta) dehydrogenase 4 |
affects binding |
EXP |
entacapone binds to HSD17B4 protein |
CTD |
PMID:19783845 |
|
NCBI chr18:43,328,903...43,417,950
Ensembl chr18:43,328,824...43,417,952
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
entacapone results in increased expression of IL1A mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
entacapone results in increased expression of IL1B mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
increases expression |
ISO |
entacapone results in increased expression of MET mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
|
|
G |
Pc |
pyruvate carboxylase |
affects binding |
EXP |
entacapone binds to PC protein |
CTD |
PMID:19783845 |
|
NCBI chr 1:201,799,374...201,898,412
Ensembl chr 1:201,804,267...201,898,380
|
|
G |
Pid1 |
phosphotyrosine interaction domain containing 1 |
decreases expression |
ISO |
entacapone results in decreased expression of PID1 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 9:85,284,335...85,503,035
Ensembl chr 9:85,284,335...85,503,044
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
entacapone results in increased expression of PTGS2 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
decreases expression |
ISO |
entacapone results in decreased expression of SLC7A11 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Slpi |
secretory leukocyte peptidase inhibitor |
decreases expression |
ISO |
entacapone results in decreased expression of SLPI mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453
|
|
G |
Snca |
synuclein alpha |
multiple interactions |
ISO |
entacapone inhibits the reaction [SNCA protein binds to SNCA protein] |
CTD |
PMID:20150427 |
|
NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
|
|
G |
Sult2a1 |
sulfotransferase family 2A member 1 |
affects binding |
EXP |
entacapone binds to SULT2A1 protein |
CTD |
PMID:19783845 |
|
NCBI chr 1:75,451,178...75,508,142
Ensembl chr 1:74,911,100...75,508,134
|
|
G |
Tnfaip6 |
TNF alpha induced protein 6 |
decreases expression |
ISO |
entacapone results in decreased expression of TNFAIP6 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases glucuronidation |
ISO |
UGT1A1 protein results in increased glucuronidation of entacapone |
CTD |
PMID:15802387 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
increases glucuronidation |
ISO |
UGT1A3 protein results in increased glucuronidation of entacapone |
CTD |
PMID:15802387 |
|
NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
increases glucuronidation decreases glucuronidation |
ISO |
UGT1A9 protein results in increased glucuronidation of entacapone UGT1A9 protein mutant form results in decreased glucuronidation of entacapone |
CTD |
PMID:15044611 PMID:15802387 PMID:16344532 |
|
NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
|
G |
Adra1a |
adrenoceptor alpha 1A |
multiple interactions |
EXP |
Lisuride binds to and results in decreased activity of ADRA1A protein; Lisuride promotes the reaction [Phenylephrine binds to and results in increased activity of ADRA1A protein] |
CTD |
PMID:16545797 |
|
NCBI chr15:40,830,125...40,935,902
Ensembl chr15:40,832,534...40,927,500
|
|
G |
Htr7 |
5-hydroxytryptamine receptor 7 |
multiple interactions |
ISO |
[Lisuride binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Lisuride binds to and results in decreased activity of HTR7 protein |
CTD |
PMID:18996971 PMID:19509219 |
|
NCBI chr 1:233,636,442...233,761,063
Ensembl chr 1:233,636,452...233,760,626
|
|
G |
Ifng |
interferon gamma |
increases expression |
ISO |
Lisuride results in increased expression of IFNG |
CTD |
PMID:7948314 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Prl |
prolactin |
multiple interactions decreases secretion |
ISO EXP |
Lisuride inhibits the reaction [Metoclopramide results in increased secretion of PRL protein]; Lisuride results in decreased expression of and results in decreased secretion of PRL protein Lisuride analog results in decreased secretion of PRL protein; Lisuride results in decreased secretion of PRL protein |
CTD |
PMID:386688 PMID:6492995 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Lisuride inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
EXP |
asoxime chloride inhibits the reaction [Memantine inhibits the reaction [Soman results in decreased activity of ACHE protein]]; Memantine inhibits the reaction [Methyl Parathion results in decreased activity of ACHE protein]; Memantine inhibits the reaction [Soman results in decreased activity of ACHE protein] |
CTD |
PMID:2241428 PMID:30682440 |
|
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
EXP |
Memantine inhibits the reaction [Streptozocin results in increased expression of APP protein modified form] |
CTD |
PMID:21290839 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Arc |
activity-regulated cytoskeleton-associated protein |
multiple interactions |
ISO |
Memantine inhibits the reaction [Lipopolysaccharides results in decreased expression of ARC protein] |
CTD |
PMID:34474083 |
|
NCBI chr 7:106,555,968...106,559,697
Ensembl chr 7:106,555,785...106,559,378
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
affects expression |
ISO |
Memantine affects the expression of BAX protein |
CTD |
PMID:29226720 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
EXP ISO |
Memantine analog inhibits the reaction [Glutamic Acid results in decreased expression of BCL2 protein]; Memantine inhibits the reaction [Glutamic Acid results in decreased expression of BCL2 protein] Memantine results in decreased expression of BCL2 protein |
CTD |
PMID:29226720 PMID:32092300 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO |
Memantine results in decreased expression of BIRC5 protein |
CTD |
PMID:29226720 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Camk2a |
calcium/calmodulin-dependent protein kinase II alpha |
multiple interactions |
EXP |
Memantine inhibits the reaction [Streptozocin results in decreased expression of CAMK2A mRNA]; Memantine inhibits the reaction [Streptozocin results in decreased expression of CAMK2A protein] |
CTD |
PMID:24333387 |
|
NCBI chr18:54,378,642...54,441,120
Ensembl chr18:54,378,784...54,438,994
|
|
G |
Capn1 |
calpain 1 |
multiple interactions |
ISO |
Memantine inhibits the reaction [Lipopolysaccharides results in increased expression of CAPN1 protein] |
CTD |
PMID:34474083 |
|
NCBI chr 1:203,275,912...203,300,848
Ensembl chr 1:203,277,344...203,300,177
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
Memantine inhibits the reaction [Lipopolysaccharides results in increased expression of CASP1 protein] |
CTD |
PMID:34474083 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression |
ISO EXP |
Memantine inhibits the reaction [benzo(e)pyrene results in increased activity of CASP3 protein]; Memantine inhibits the reaction [catechol results in increased activity of CASP3 protein]; Memantine inhibits the reaction [salsolinol results in increased activity of CASP3 protein]; Memantine inhibits the reaction [Staurosporine results in increased activity of CASP3 protein] Memantine results in increased expression of CASP3 protein Memantine inhibits the reaction [Ethanol results in increased expression of and results in increased activity of CASP3 protein] Memantine inhibits the reaction [Streptozocin results in increased activity of CASP3 protein]; Memantine inhibits the reaction [Streptozocin results in increased expression of CASP3 mRNA] |
CTD |
PMID:17996985 PMID:19959636 PMID:20347921 PMID:24333387 PMID:29226720 PMID:29800586 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
Memantine inhibits the reaction [benzo(e)pyrene results in increased activity of CASP7 protein]; Memantine inhibits the reaction [catechol results in increased activity of CASP7 protein] |
CTD |
PMID:19959636 PMID:20347921 |
|
NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp9 |
caspase 9 |
increases expression |
ISO |
Memantine results in increased expression of CASP9 protein |
CTD |
PMID:29226720 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
Memantine results in decreased expression of CCND1 protein |
CTD |
PMID:29226720 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
increases expression |
ISO |
Memantine results in increased expression of CDK4 protein |
CTD |
PMID:29226720 |
|
NCBI chr 7:62,885,647...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
Memantine inhibits the reaction [Streptozocin results in decreased phosphorylation of CREB1 protein] |
CTD |
PMID:23562514 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Dlg4 |
discs large MAGUK scaffold protein 4 |
multiple interactions |
EXP ISO |
Memantine inhibits the reaction [Streptozocin results in decreased expression of DLG4 protein] Memantine inhibits the reaction [Lipopolysaccharides results in decreased expression of DLG4 protein] |
CTD |
PMID:24333387 PMID:34474083 |
|
NCBI chr10:54,740,700...54,769,097
Ensembl chr10:54,739,470...54,767,153
|
|
G |
Dlgap2 |
DLG associated protein 2 |
multiple interactions |
EXP |
Memantine inhibits the reaction [Streptozocin results in decreased expression of DLGAP2 mRNA] |
CTD |
PMID:24333387 |
|
NCBI chr16:74,786,771...75,496,402
Ensembl chr16:74,791,509...75,496,407
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions |
EXP ISO |
Memantine inhibits the reaction [Streptozocin results in increased expression of GFAP mRNA]; Memantine inhibits the reaction [Streptozocin results in increased expression of GFAP protein] Memantine inhibits the reaction [Lipopolysaccharides results in increased expression of GFAP protein] |
CTD |
PMID:24333387 PMID:34474083 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
multiple interactions |
ISO |
Memantine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of GRIN2B protein] |
CTD |
PMID:34474083 |
|
NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Memantine analog inhibits the reaction [Glutamic Acid results in decreased phosphorylation of and results in increased activity of GSK3B protein]]; Memantine analog inhibits the reaction [Glutamic Acid results in decreased phosphorylation of and results in increased activity of GSK3B protein] |
CTD |
PMID:32092300 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
Memantine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] |
CTD |
PMID:34474083 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions |
EXP |
Memantine inhibits the reaction [Streptozocin results in increased expression of ITGAM mRNA]; Memantine inhibits the reaction [Streptozocin results in increased expression of ITGAM protein] |
CTD |
PMID:24333387 |
|
NCBI chr 1:182,659,047...182,709,495
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
EXP |
Memantine inhibits the reaction [Streptozocin results in decreased phosphorylation of MAPK1 protein] |
CTD |
PMID:23562514 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP |
Memantine inhibits the reaction [Streptozocin results in decreased phosphorylation of MAPK3 protein] |
CTD |
PMID:23562514 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
ISO |
Memantine results in decreased expression of MYC protein |
CTD |
PMID:29226720 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nefl |
neurofilament light chain |
multiple interactions |
EXP |
Memantine inhibits the reaction [N-Methylaspartate results in decreased expression of NEFL mRNA]; Memantine inhibits the reaction [Rotenone results in decreased expression of NEFL mRNA] |
CTD |
PMID:31969611 |
|
NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
Memantine inhibits the reaction [Lipopolysaccharides results in increased expression of NLRP3 protein] |
CTD |
PMID:34474083 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Penk |
proenkephalin |
multiple interactions |
EXP |
Memantine inhibits the reaction [Haloperidol results in increased expression of PENK mRNA] |
CTD |
PMID:14642644 |
|
NCBI chr 5:17,183,799...17,189,160
Ensembl chr 5:17,183,806...17,189,129
|
|
G |
Ppp2ca |
protein phosphatase 2 catalytic subunit alpha |
multiple interactions |
ISO |
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Okadaic Acid co-treated with Fingolimod Hydrochloride co-treated with Memantine] results in increased expression of PPP2CA mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Okadaic Acid co-treated with Fingolimod Hydrochloride co-treated with Memantine] results in increased expression of PPP2CA protein |
CTD |
PMID:33069748 |
|
NCBI chr10:36,358,110...36,377,864
Ensembl chr10:36,358,101...36,377,862
|
|
G |
Prkcg |
protein kinase C, gamma |
increases expression |
EXP |
Memantine results in increased expression of PRKCG mRNA |
CTD |
PMID:11169168 |
|
NCBI chr 1:65,832,851...65,860,676
Ensembl chr 1:65,832,855...65,859,384
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP ISO |
Memantine inhibits the reaction [Streptozocin results in increased expression of TNF protein] Memantine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:24333387 PMID:34474083 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Htr2b |
5-hydroxytryptamine receptor 2B |
affects binding multiple interactions |
ISO |
mesulergine binds to HTR2B protein Fluoxetine promotes the reaction [mesulergine binds to HTR2B protein] |
CTD |
PMID:11930908 |
|
NCBI chr 9:86,735,793...86,756,640
Ensembl chr 9:86,742,102...86,755,108
|
|
G |
Htr2c |
5-hydroxytryptamine receptor 2C |
multiple interactions affects binding |
EXP ISO |
Carbamazepine inhibits the reaction [Pilocarpine affects the reaction [mesulergine binds to HTR2C protein]]; Carbamazepine inhibits the reaction [Pilocarpine inhibits the reaction [mesulergine binds to HTR2C protein]]; Pilocarpine affects the reaction [mesulergine binds to HTR2C protein]; Pilocarpine inhibits the reaction [mesulergine binds to HTR2C protein]; Plant Extracts inhibits the reaction [Pilocarpine affects the reaction [mesulergine binds to HTR2C protein]]; Plant Extracts inhibits the reaction [Pilocarpine inhibits the reaction [mesulergine binds to HTR2C protein]] N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [mesulergine binds to HTR2C protein] |
CTD |
PMID:18083778 PMID:19439326 PMID:19700373 PMID:29458138 |
|
NCBI chr X:110,640,777...110,870,288
Ensembl chr X:110,641,153...110,870,287
|
|
G |
Htr7 |
5-hydroxytryptamine receptor 7 |
multiple interactions affects binding |
ISO |
[mesulergine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; mesulergine inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein] mesulergine binds to HTR7 protein |
CTD |
PMID:14578406 PMID:20827463 |
|
NCBI chr 1:233,636,442...233,761,063
Ensembl chr 1:233,636,452...233,760,626
|
|
G |
Prl |
prolactin |
multiple interactions |
EXP |
mesulergine inhibits the reaction [Diethylstilbestrol results in increased secretion of PRL protein] |
CTD |
PMID:1421203 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
methixene results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
|
G |
A2m |
alpha-2-macroglobulin |
affects expression |
EXP |
Orphenadrine affects the expression of A2M mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786
|
|
G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
affects expression |
EXP |
Orphenadrine affects the expression of ABCB1B mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
EXP |
[Orphenadrine co-treated with Diethylnitrosamine] results in increased expression of ABCC2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
affects expression |
EXP |
Orphenadrine affects the expression of ABCC3 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcd2 |
ATP binding cassette subfamily D member 2 |
affects expression |
EXP |
Orphenadrine affects the expression of ABCD2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 7:122,263,034...122,311,642
Ensembl chr 7:122,263,032...122,311,642
|
|
G |
Ablim3 |
actin binding LIM protein family, member 3 |
affects expression |
EXP |
Orphenadrine affects the expression of ABLIM3 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr18:55,256,135...55,376,629
Ensembl chr18:55,257,583...55,376,380
|
|
G |
Ace2 |
angiotensin I converting enzyme 2 |
affects expression |
EXP |
Orphenadrine affects the expression of ACE2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Acer3 |
alkaline ceramidase 3 |
affects expression |
EXP |
Orphenadrine affects the expression of ACER3 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:152,504,180...152,606,596
Ensembl chr 1:152,504,186...152,606,591
|
|
G |
Acsl5 |
acyl-CoA synthetase long-chain family member 5 |
affects expression |
EXP |
Orphenadrine affects the expression of ACSL5 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:254,289,513...254,336,608
Ensembl chr 1:254,292,521...254,336,607
|
|
G |
Acsm3 |
acyl-CoA synthetase medium-chain family member 3 |
affects expression |
EXP |
Orphenadrine affects the expression of ACSM3 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:174,133,260...174,159,966
Ensembl chr 1:174,133,288...174,160,184
|
|
G |
Adgrg2 |
adhesion G protein-coupled receptor G2 |
affects expression |
EXP |
Orphenadrine affects the expression of ADGRG2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr X:34,297,402...34,422,590
Ensembl chr X:34,297,402...34,422,609
|
|
G |
Adgrv1 |
adhesion G protein-coupled receptor V1 |
affects expression |
EXP |
Orphenadrine affects the expression of ADGRV1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 2:11,331,434...11,911,713
Ensembl chr 2:11,331,442...11,911,688
|
|
G |
Adh4 |
alcohol dehydrogenase 4 (class II), pi polypeptide |
affects expression |
EXP |
Orphenadrine affects the expression of ADH4 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 2:226,948,717...226,966,747
Ensembl chr 2:226,947,466...226,987,591
|
|
G |
Adora1 |
adenosine A1 receptor |
affects expression |
EXP |
Orphenadrine affects the expression of ADORA1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr13:45,658,872...45,695,821
Ensembl chr13:45,658,872...45,695,801
|
|
G |
Adora2a |
adenosine A2a receptor |
affects expression |
EXP |
Orphenadrine affects the expression of ADORA2A mRNA |
CTD |
PMID:23665939 |
|
NCBI chr20:13,315,848...13,333,386
Ensembl chr20:13,315,853...13,333,386
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
affects expression |
EXP |
Orphenadrine affects the expression of ADRB2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Ajuba |
ajuba LIM protein |
affects expression |
EXP |
Orphenadrine affects the expression of JUB mRNA |
CTD |
PMID:23665939 |
|
NCBI chr15:28,019,775...28,031,537
Ensembl chr15:28,019,778...28,030,021
|
|
G |
Akr7a3 |
aldo-keto reductase family 7 member A3 |
affects expression |
EXP |
Orphenadrine affects the expression of AKR7A3 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 5:151,590,968...151,601,394
Ensembl chr 5:151,584,479...151,601,394
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
affects expression |
EXP |
Orphenadrine affects the expression of ALDH1A1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
affects expression |
EXP |
Orphenadrine affects the expression of ALPL mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Als2cl |
ALS2 C-terminal like |
affects expression |
EXP |
Orphenadrine affects the expression of ALS2CL mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 8:110,863,753...110,884,434
Ensembl chr 8:110,864,975...110,884,419
|
|
G |
Amigo3 |
adhesion molecule with Ig like domain 3 |
affects expression |
EXP |
Orphenadrine affects the expression of AMIGO3 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 8:108,741,899...108,743,425
Ensembl chr 8:108,693,060...108,744,555
|
|
G |
Amotl2 |
angiomotin like 2 |
affects expression |
EXP |
Orphenadrine affects the expression of AMOTL2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 8:103,303,368...103,319,161
Ensembl chr 8:103,302,992...103,318,910
|
|
G |
Angptl4 |
angiopoietin-like 4 |
affects expression |
EXP |
Orphenadrine affects the expression of ANGPTL4 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519
|
|
G |
Angptl6 |
angiopoietin-like 6 |
affects expression |
EXP |
Orphenadrine affects the expression of ANGPTL6 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 8:19,413,617...19,419,925
Ensembl chr 8:19,413,619...19,419,925
|
|
G |
Ankrd9 |
ankyrin repeat domain 9 |
affects expression |
EXP |
Orphenadrine affects the expression of ANKRD9 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 6:130,001,914...130,008,792
Ensembl chr 6:129,998,486...130,008,923
|
|
G |
Ano1 |
anoctamin 1 |
affects expression |
EXP |
Orphenadrine affects the expression of ANO1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:199,751,439...199,900,099
Ensembl chr 1:199,751,439...199,900,069
|
|
G |
Anxa5 |
annexin A5 |
affects expression |
EXP |
Orphenadrine affects the expression of ANXA5 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 2:119,314,007...119,344,703
Ensembl chr 2:119,314,007...119,353,369
|
|
G |
App |
amyloid beta precursor protein |
affects expression |
EXP |
Orphenadrine affects the expression of APP mRNA |
CTD |
PMID:23665939 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Aqp9 |
aquaporin 9 |
affects expression |
EXP |
Orphenadrine affects the expression of AQP9 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 8:71,797,231...71,837,485
Ensembl chr 8:71,797,234...71,837,395
|
|
G |
Arhgap10 |
Rho GTPase activating protein 10 |
affects expression |
EXP |
Orphenadrine affects the expression of ARHGAP10 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr19:30,448,572...30,710,315
Ensembl chr19:30,448,637...30,710,313
|
|
G |
Arhgap22 |
Rho GTPase activating protein 22 |
affects expression |
EXP |
Orphenadrine affects the expression of ARHGAP22 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr16:8,473,806...8,631,552
Ensembl chr16:8,476,306...8,631,548
|
|
G |
Arhgef10 |
Rho guanine nucleotide exchange factor 10 |
affects expression |
EXP |
Orphenadrine affects the expression of ARHGEF10 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr16:74,647,147...74,738,784
Ensembl chr16:74,647,153...74,738,173
|
|
G |
Arhgef15 |
Rho guanine nucleotide exchange factor 15 |
affects expression |
EXP |
Orphenadrine affects the expression of ARHGEF15 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr10:53,650,521...53,662,914
Ensembl chr10:53,650,553...53,663,913
|
|
G |
Armcx1 |
armadillo repeat containing, X-linked 1 |
affects expression |
EXP |
Orphenadrine affects the expression of ARMCX1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr X:97,898,969...97,902,874
Ensembl chr X:97,898,883...97,903,299
|
|
G |
Arrdc2 |
arrestin domain containing 2 |
affects expression |
EXP |
Orphenadrine affects the expression of ARRDC2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr16:18,601,897...18,606,029
Ensembl chr16:18,601,897...18,606,029
|
|
G |
Atf3 |
activating transcription factor 3 |
affects expression |
EXP |
Orphenadrine affects the expression of ATF3 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atp2b2 |
ATPase plasma membrane Ca2+ transporting 2 |
affects expression |
EXP |
Orphenadrine affects the expression of ATP2B2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 4:146,896,332...147,140,665
Ensembl chr 4:146,896,332...147,140,665
|
|
G |
Atrnl1 |
attractin like 1 |
affects expression |
EXP |
Orphenadrine affects the expression of ATRNL1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:256,670,976...257,219,291
Ensembl chr 1:256,670,627...257,213,197
|
|
G |
Azin2 |
antizyme inhibitor 2 |
affects expression |
EXP |
Orphenadrine affects the expression of AZIN2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 5:141,281,310...141,310,415
Ensembl chr 5:141,281,249...141,310,397
|
|
G |
B3gnt9 |
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 9 |
affects expression |
EXP |
Orphenadrine affects the expression of B3GNT9 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr19:33,129,740...33,134,048
Ensembl chr19:33,128,142...33,132,344
|
|
G |
B4galt6 |
beta-1,4-galactosyltransferase 6 |
affects expression |
EXP |
Orphenadrine affects the expression of B4GALT6 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr18:11,958,382...12,015,247
Ensembl chr18:11,958,390...12,015,247
|
|
G |
Bambi |
BMP and activin membrane-bound inhibitor |
affects expression |
EXP |
Orphenadrine affects the expression of BAMBI mRNA |
CTD |
PMID:23665939 |
|
NCBI chr17:54,121,251...54,125,816
Ensembl chr17:54,121,255...54,126,060
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
affects expression |
EXP |
Orphenadrine affects the expression of BBC3 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bcl6 |
BCL6, transcription repressor |
affects expression |
EXP |
Orphenadrine affects the expression of BCL6 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr11:76,854,090...76,877,389
Ensembl chr11:76,854,090...76,877,389
|
|
G |
Bco2 |
beta-carotene oxygenase 2 |
affects expression |
EXP |
Orphenadrine affects the expression of BCO2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 8:50,882,174...50,907,676
Ensembl chr 8:50,882,181...50,915,467
|
|
G |
Bhlha15 |
basic helix-loop-helix family, member a15 |
affects expression |
EXP |
Orphenadrine affects the expression of BHLHA15 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr12:10,420,465...10,424,641
Ensembl chr12:10,420,467...10,424,713
|
|
G |
Bicc1 |
BicC family RNA binding protein 1 |
affects expression |
EXP |
Orphenadrine affects the expression of BICC1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr20:17,449,644...17,686,775
Ensembl chr20:17,449,560...17,686,776
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
affects expression |
EXP |
Orphenadrine affects the expression of BMP4 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306
|
|
G |
Btbd7 |
BTB domain containing 7 |
affects expression |
EXP |
Orphenadrine affects the expression of BTBD7 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 6:121,920,365...122,010,114
Ensembl chr 6:121,923,023...121,972,405
|
|
G |
C1qtnf2 |
C1q and TNF related 2 |
affects expression |
EXP |
Orphenadrine affects the expression of C1QTNF2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr10:27,941,948...27,958,926
Ensembl chr10:27,941,948...27,959,185
|
|
G |
C8h15orf39 |
similar to human chromosome 15 open reading frame 39 |
affects expression |
EXP |
Orphenadrine affects the expression of C8H15ORF39 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 8:57,646,324...57,655,896
Ensembl chr 8:57,645,756...57,655,941
|
|
G |
Calcrl |
calcitonin receptor like receptor |
affects expression |
EXP |
Orphenadrine affects the expression of CALCRL mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 3:69,428,348...69,525,910
Ensembl chr 3:69,430,120...69,525,910
|
|
G |
Car1 |
carbonic anhydrase 1 |
affects expression |
EXP |
Orphenadrine affects the expression of CA1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 2:86,829,436...86,872,209
Ensembl chr 2:86,861,897...86,872,208
|
|
G |
Car2 |
carbonic anhydrase 2 |
affects expression |
EXP |
Orphenadrine affects the expression of CA2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818
|
|
G |
Car3 |
carbonic anhydrase 3 |
affects expression |
EXP |
Orphenadrine affects the expression of CA3 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280
|
|
G |
Card19 |
caspase recruitment domain family, member 19 |
affects expression |
EXP |
Orphenadrine affects the expression of CARD19 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr17:15,432,572...15,445,318
Ensembl chr17:15,432,612...15,445,318
|
|
G |
Casp2 |
caspase 2 |
affects expression |
EXP |
Orphenadrine affects the expression of CASP2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379
|
|
G |
Cblc |
Cbl proto-oncogene C |
affects expression |
EXP |
Orphenadrine affects the expression of CBLC mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:79,439,975...79,456,755
Ensembl chr 1:79,439,977...79,456,755
|
|
G |
Cbx4 |
chromobox 4 |
affects expression |
EXP |
Orphenadrine affects the expression of CBX4 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr10:104,337,140...104,343,210
Ensembl chr10:104,336,876...104,356,706
|
|
G |
Ccdc68 |
coiled-coil domain containing 68 |
affects expression |
EXP |
Orphenadrine affects the expression of CCDC68 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr18:63,541,828...63,584,122
Ensembl chr18:63,541,896...63,584,119
|
|
G |
Ccn1 |
cellular communication network factor 1 |
affects expression |
EXP |
Orphenadrine affects the expression of CCN1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
EXP |
Orphenadrine promotes the reaction [Diethylnitrosamine results in increased expression of CCND1 mRNA] |
CTD |
PMID:23665939 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd2 |
cyclin D2 |
affects expression |
EXP |
Orphenadrine affects the expression of CCND2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Cd24 |
CD24 molecule |
affects expression |
EXP |
Orphenadrine affects the expression of CD24 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr20:47,074,353...47,079,662
Ensembl chr20:47,073,512...47,079,662
|
|
G |
Cd276 |
Cd276 molecule |
affects expression |
EXP |
Orphenadrine affects the expression of CD276 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 8:58,937,751...58,968,082
Ensembl chr 8:58,937,751...58,968,380
|
|
G |
Cd36 |
CD36 molecule |
affects expression |
EXP |
Orphenadrine affects the expression of CD36 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cdc42ep1 |
CDC42 effector protein 1 |
affects expression |
EXP |
Orphenadrine affects the expression of CDC42EP1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 7:110,395,287...110,403,203
Ensembl chr 7:110,395,332...110,403,200
|
|
G |
Cdh3 |
cadherin 3 |
affects expression |
EXP |
Orphenadrine affects the expression of CDH3 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr19:34,393,596...34,444,084
Ensembl chr19:34,393,727...34,444,084
|
|
G |
Cdr2 |
cerebellar degeneration-related protein 2 |
affects expression |
EXP |
Orphenadrine affects the expression of CDR2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:175,502,837...175,527,746
Ensembl chr 1:175,502,838...175,537,472
|
|
G |
Ces2h |
carboxylesterase 2H |
affects expression |
EXP |
Orphenadrine affects the expression of CES2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
|
|
G |
Cfap68 |
cilia and flagella associated protein 68 |
affects expression |
EXP |
Orphenadrine affects the expression of CFAP68 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 8:51,107,663...51,113,192
Ensembl chr 8:51,107,721...51,113,420
|
|
G |
Cgref1 |
cell growth regulator with EF hand domain 1 |
affects expression |
EXP |
Orphenadrine affects the expression of CGREF1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 6:25,431,846...25,443,853
Ensembl chr 6:25,431,799...25,443,852
|
|
G |
Chmp4c |
charged multivesicular body protein 4C |
affects expression |
EXP |
Orphenadrine affects the expression of CHMP4C mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 2:91,391,729...91,428,652
Ensembl chr 2:91,388,530...91,428,668
|
|
G |
Cidea |
cell death-inducing DFFA-like effector a |
affects expression |
EXP |
Orphenadrine affects the expression of CIDEA mRNA |
CTD |
PMID:23665939 |
|
NCBI chr18:60,894,917...60,920,485
Ensembl chr18:60,894,874...60,920,481
|
|
G |
Cish |
cytokine inducible SH2-containing protein |
affects expression |
EXP |
Orphenadrine affects the expression of CISH mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 8:107,972,306...107,977,254
Ensembl chr 8:107,972,306...107,977,250
|
|
G |
Clcf1 |
cardiotrophin-like cytokine factor 1 |
affects expression |
EXP |
Orphenadrine affects the expression of CLCF1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:201,507,763...201,517,607
Ensembl chr 1:201,507,859...201,517,605
|
|
G |
Cldn23 |
claudin 23 |
affects expression |
EXP |
Orphenadrine affects the expression of CLDN23 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr16:56,413,677...56,415,401
Ensembl chr16:56,413,381...56,415,523
|
|
G |
Cndp1 |
carnosine dipeptidase 1 |
affects expression |
EXP |
Orphenadrine affects the expression of CNDP1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr18:77,984,886...78,030,837
Ensembl chr18:77,984,907...78,007,765
|
|
G |
Col4a3 |
collagen type IV alpha 3 chain |
affects expression |
EXP |
Orphenadrine affects the expression of COL4A3 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 9:83,875,958...84,004,955
Ensembl chr 9:83,875,561...84,001,895
|
|
G |
Cpt1b |
carnitine palmitoyltransferase 1B |
affects expression |
EXP |
Orphenadrine affects the expression of CPT1B mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 7:120,491,354...120,500,833
Ensembl chr 7:120,491,354...120,500,404
|
|
G |
Crat |
carnitine O-acetyltransferase |
affects expression |
EXP |
Orphenadrine affects the expression of CRAT mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 3:13,675,684...13,689,282
Ensembl chr 3:13,675,684...13,689,255
|
|
G |
Crlf2 |
cytokine receptor-like factor 2 |
affects expression |
EXP |
Orphenadrine affects the expression of CRLF2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr14:103,943...108,643
Ensembl chr14:103,939...108,642
|
|
G |
Cryab |
crystallin, alpha B |
affects expression |
EXP |
Orphenadrine affects the expression of CRYAB mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157
|
|
G |
Cryl1 |
crystallin, lambda 1 |
affects expression |
EXP |
Orphenadrine affects the expression of CRYL1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr15:31,427,011...31,545,997
Ensembl chr15:31,427,054...31,545,997
|
|
G |
Csmd1 |
CUB and Sushi multiple domains 1 |
affects expression |
EXP |
Orphenadrine affects the expression of CSMD1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr16:72,218,189...73,818,380
Ensembl chr16:72,218,503...73,817,614
|
|
G |
Csrnp1 |
cysteine and serine rich nuclear protein 1 |
affects expression |
EXP |
Orphenadrine affects the expression of CSRNP1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 8:119,704,712...119,717,767
Ensembl chr 8:119,704,713...119,718,183
|
|
G |
Cst9l |
cystatin 9-like |
affects expression |
EXP |
Orphenadrine affects the expression of CST9L mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 3:136,288,093...136,290,906
Ensembl chr 3:136,288,093...136,290,906
|
|
G |
Ctps1 |
CTP synthase 1 |
affects expression |
EXP |
Orphenadrine affects the expression of CTPS mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 5:134,125,022...134,154,155
Ensembl chr 5:134,125,025...134,154,180
|
|
G |
Ctrb1 |
chymotrypsinogen B1 |
affects expression |
EXP |
Orphenadrine affects the expression of CTRB mRNA |
CTD |
PMID:23665939 |
|
NCBI chr19:39,652,931...39,657,666
Ensembl chr19:39,652,933...39,657,688
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions affects expression |
EXP |
[Orphenadrine co-treated with Diethylnitrosamine] results in increased expression of CYP1A1 mRNA Orphenadrine affects the expression of CYP1A1 mRNA |
CTD |
PMID:23665939 PMID:23665940 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions decreases activity |
ISO EXP |
Orphenadrine inhibits the reaction [CYP1A2 protein results in decreased ethylation of 7-ethoxy-4-trifluoromethylcoumarin]; Orphenadrine inhibits the reaction [CYP1A2 protein results in increased chemical synthesis of 7-hydroxy-4-trifluoromethylcoumarin] Orphenadrine results in decreased activity of CYP1A2 protein Orphenadrine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein] |
CTD |
PMID:9241656 PMID:18493746 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2b15 |
cytochrome P450, family 2, subfamily b, polypeptide 15 |
affects expression |
EXP |
Orphenadrine affects the expression of CYP2B15 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:82,094,188...82,106,492
Ensembl chr 1:82,094,180...82,106,492
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
affects expression multiple interactions |
EXP |
Orphenadrine affects the expression of CYP2B2 mRNA [Orphenadrine co-treated with Phenobarbital] affects the expression of CYP2B2 mRNA |
CTD |
PMID:23665939 PMID:23665940 |
|
NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
decreases activity multiple interactions |
ISO |
Orphenadrine results in decreased activity of CYP2B6 protein Orphenadrine inhibits the reaction [CYP2B6 protein results in decreased ethylation of 7-ethoxy-4-trifluoromethylcoumarin]; Orphenadrine inhibits the reaction [CYP2B6 protein results in increased chemical synthesis of 7-hydroxy-4-trifluoromethylcoumarin] |
CTD |
PMID:9241656 PMID:12464242 PMID:15306208 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c12 |
cytochrome P450, family 2, subfamily c, polypeptide 12 |
affects expression |
EXP |
Orphenadrine affects the expression of CYP2C12 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:238,699,859...238,757,011
Ensembl chr 1:238,699,854...238,757,019
|
|
G |
Cyp2c24 |
cytochrome P450, family 2, subfamily c, polypeptide 24 |
affects expression |
EXP |
Orphenadrine affects the expression of CYP2C24 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:236,873,967...236,936,238
Ensembl chr 1:236,873,967...236,936,238
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions decreases activity |
ISO |
Orphenadrine inhibits the reaction [CYP2E1 protein results in decreased ethylation of 7-ethoxy-4-trifluoromethylcoumarin]; Orphenadrine inhibits the reaction [CYP2E1 protein results in increased chemical synthesis of 7-hydroxy-4-trifluoromethylcoumarin] Orphenadrine results in decreased activity of CYP2E1 protein |
CTD |
PMID:9241656 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
affects expression |
EXP |
Orphenadrine affects the expression of CYP3A62 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr12:16,397,998...16,433,833
Ensembl chr12:16,397,998...16,433,833
|
|
G |
Cyp4a1 |
cytochrome P450, family 4, subfamily a, polypeptide 1 |
affects expression |
EXP |
Orphenadrine affects the expression of CYP4A1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 5:129,123,323...129,137,464
Ensembl chr 5:129,123,336...129,137,464
|
|
G |
Cyp4a8 |
cytochrome P450, family 4, subfamily a, polypeptide 8 |
affects expression |
EXP |
Orphenadrine affects the expression of CYP4A8 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 5:128,702,130...128,733,476
Ensembl chr 5:128,702,131...128,733,476
|
|
G |
Cyp4b1 |
cytochrome P450, family 4, subfamily b, polypeptide 1 |
affects expression |
EXP |
Orphenadrine affects the expression of CYP4B1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 5:129,139,019...129,176,860
Ensembl chr 5:129,139,038...129,156,348
|
|
G |
Cyp4f5 |
cytochrome P450, family 4, subfamily f, polypeptide 5 |
affects expression |
EXP |
Orphenadrine affects the expression of CYP4F5 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 7:11,544,040...11,558,982
Ensembl chr 7:11,544,082...11,558,978
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
affects expression |
EXP |
Orphenadrine affects the expression of CYP7A1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
affects expression |
EXP |
Orphenadrine affects the expression of CYP8B1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Cystm1 |
cysteine-rich transmembrane module containing 1 |
affects expression |
EXP |
Orphenadrine affects the expression of CYSTM1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr18:27,945,862...28,013,509
Ensembl chr18:27,951,653...28,013,510
|
|
G |
Cyyr1 |
cysteine and tyrosine rich 1 |
affects expression |
EXP |
Orphenadrine affects the expression of CYYR1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr11:24,557,620...24,664,007
Ensembl chr11:24,515,316...24,663,961
|
|
G |
Dact2 |
dishevelled-binding antagonist of beta-catenin 2 |
affects expression |
EXP |
Orphenadrine affects the expression of DACT2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:55,181,023...55,191,026
Ensembl chr 1:55,181,024...55,191,096
|
|
G |
Defb36 |
defensin beta 36 |
affects expression |
EXP |
Orphenadrine affects the expression of DEFB36 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 3:141,078,001...141,086,832
Ensembl chr 3:141,086,058...141,086,728
|
|
G |
Dip2a |
disco-interacting protein 2 homolog A |
affects expression |
EXP |
Orphenadrine affects the expression of DIP2A mRNA |
CTD |
PMID:23665939 |
|
NCBI chr20:12,284,566...12,371,068
Ensembl chr20:12,284,654...12,370,217
|
|
G |
Dll1 |
delta like canonical Notch ligand 1 |
affects expression |
EXP |
Orphenadrine affects the expression of DLL1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:56,312,062...56,320,177
Ensembl chr 1:56,312,066...56,320,179
|
|
G |
Dnhd1 |
dynein heavy chain domain 1 |
affects expression |
EXP |
Orphenadrine affects the expression of DNHD1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:159,990,785...160,077,990
Ensembl chr 1:159,990,438...160,074,858
|
|
G |
Dpp6 |
dipeptidyl peptidase like 6 |
affects expression |
EXP |
Orphenadrine affects the expression of DPP6 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 4:7,589,386...8,508,666
Ensembl chr 4:7,591,009...8,508,532
|
|
G |
Dram1 |
DNA-damage regulated autophagy modulator 1 |
affects expression |
EXP |
Orphenadrine affects the expression of DRAM1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 7:22,742,794...22,776,888
Ensembl chr 7:22,742,849...22,776,765
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
affects expression |
EXP |
Orphenadrine affects the expression of DUSP1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr10:16,680,489...16,683,276
|
|
G |
Dusp10 |
dual specificity phosphatase 10 |
affects expression |
EXP |
Orphenadrine affects the expression of DUSP10 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr13:95,613,716...95,651,716
Ensembl chr13:95,614,292...95,651,716
|
|
G |
Dusp13 |
dual specificity phosphatase 13 |
affects expression |
EXP |
Orphenadrine affects the expression of DUSP13 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr15:2,559,720...2,575,105
Ensembl chr15:2,533,547...2,575,539
|
|
G |
Dusp16 |
dual specificity phosphatase 16 |
affects expression |
EXP |
Orphenadrine affects the expression of DUSP16 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 4:167,546,780...167,629,949
Ensembl chr 4:167,548,155...167,629,980
|
|
G |
Dusp8 |
dual specificity phosphatase 8 |
affects expression |
EXP |
Orphenadrine affects the expression of DUSP8 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:197,167,392...197,184,285
Ensembl chr 1:197,169,422...197,182,921
|
|
G |
Eeig1 |
estrogen-induced osteoclastogenesis regulator 1 |
affects expression |
EXP |
Orphenadrine affects the expression of EEIG1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 3:15,823,147...15,854,651
Ensembl chr 3:15,823,144...15,854,643
|
|
G |
Eeig2 |
EEIG family member 2 |
affects expression |
EXP |
Orphenadrine affects the expression of EEIG2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 2:196,608,499...196,663,371
Ensembl chr 2:196,608,499...196,663,371
|
|
G |
Efemp1 |
EGF containing fibulin extracellular matrix protein 1 |
affects expression |
EXP |
Orphenadrine affects the expression of EFEMP1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr14:102,610,813...102,690,027
Ensembl chr14:102,610,908...102,690,018
|
|
G |
Egln3 |
egl-9 family hypoxia-inducible factor 3 |
affects expression |
EXP |
Orphenadrine affects the expression of EGLN3 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 6:71,650,297...71,675,766
Ensembl chr 6:71,650,297...71,675,766
|
|
G |
Egr1 |
early growth response 1 |
affects expression |
EXP |
Orphenadrine affects the expression of EGR1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Emilin1 |
elastin microfibril interfacer 1 |
affects expression |
EXP |
Orphenadrine affects the expression of EMILIN1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 6:25,455,974...25,463,736
Ensembl chr 6:25,445,298...25,463,698
|
|
G |
Epha2 |
Eph receptor A2 |
affects expression |
EXP |
Orphenadrine affects the expression of EPHA2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 5:153,605,644...153,634,115
Ensembl chr 5:153,605,644...153,634,117
|
|
G |
Ephb4 |
EPH receptor B4 |
affects expression |
EXP |
Orphenadrine affects the expression of EPHB4 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr12:19,326,411...19,351,667
Ensembl chr12:19,326,427...19,351,314
|
|
G |
Eri2 |
ERI1 exoribonuclease family member 2 |
affects expression |
EXP |
Orphenadrine affects the expression of ERI2 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:174,140,831...174,168,757
Ensembl chr 1:174,141,993...174,168,665
|
|
G |
F8 |
coagulation factor VIII |
affects expression |
EXP |
Orphenadrine affects the expression of F8 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr18:140,848...172,330
Ensembl chr18:140,955...171,857
|
|
G |
Fam89a |
family with sequence similarity 89, member A |
affects expression |
EXP |
Orphenadrine affects the expression of FAM89A mRNA |
CTD |
PMID:23665939 |
|
NCBI chr19:52,710,003...52,722,591
Ensembl chr19:52,710,019...52,722,631
|
|
G |
Fbxo27 |
F-box protein 27 |
affects expression |
EXP |
Orphenadrine affects the expression of FBXO27 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 1:83,965,426...83,987,781
Ensembl chr 1:83,965,986...83,987,778
|
|
G |
Fer1l5 |
fer-1-like family member 5 |
affects expression |
EXP |
Orphenadrine affects the expression of FER1L5 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 9:38,605,835...38,661,869
Ensembl chr 9:38,607,843...38,660,425
|
|
G |
Fgd5 |
FYVE, RhoGEF and PH domain containing 5 |
affects expression |
EXP |
Orphenadrine affects the expression of FGD5 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr 4:124,497,061...124,594,564
Ensembl chr 4:124,497,068...124,594,563
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
affects expression |
EXP |
Orphenadrine affects the expression of FLT1 mRNA |
CTD |
PMID:23665939 |
|
NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
|
|
G |
| |